The risk factors for ovarian cancer are associated with a higher frequency of ovulations.

Ovarian cancer is a common malignancy in women, ranking fifth in frequency. It is most commonly diagnosed in women over the age of 60 and has a poor prognosis due to late detection. The majority of ovarian cancers, around 90%, are of epithelial origin, with serous carcinomas accounting for 70-80% of cases. Interestingly, recent research suggests that many ovarian cancers may actually originate in the distal end of the fallopian tube. Risk factors for ovarian cancer include a family history of BRCA1 or BRCA2 gene mutations, early menarche, late menopause, and nulliparity.

Clinical features of ovarian cancer are often vague and can include abdominal distension and bloating, abdominal and pelvic pain, urinary symptoms such as urgency, early satiety, and diarrhea. The initial diagnostic test recommended by NICE is a CA125 blood test, although this can also be elevated in other conditions such as endometriosis and benign ovarian cysts. If the CA125 level is raised, an urgent ultrasound scan of the abdomen and pelvis should be ordered. However, a CA125 test should not be used for screening asymptomatic women. Diagnosis of ovarian cancer is difficult and usually requires a diagnostic laparotomy.

Management of ovarian cancer typically involves a combination of surgery and platinum-based chemotherapy. Unfortunately, 80% of women have advanced disease at the time of diagnosis, leading to a 5-year survival rate of only 46%. It was previously thought that infertility treatment increased the risk of ovarian cancer due to increased ovulation, but recent evidence suggests that this is not a significant factor. In fact, the combined oral contraceptive pill and multiple pregnancies have been shown to reduce the risk of ovarian cancer by reducing the number of ovulations.

GBS is a type of bacteria commonly found in the vagina of many women. While it is generally harmless, it can cause serious infections in newborns, leading to significant health problems and even death.

If GBS is detected during pregnancy, it does not require immediate treatment as it will not reduce the likelihood of transmission to the baby during delivery. However, intravenous benzylpenicillin or clindamycin is necessary during labor to reduce the risk of transmission. This applies to GBS found in vaginal swabs and urine, and appropriate antibiotics are required for GBS urinary tract infections during pregnancy.

There is currently no screening program for GBS in the UK, and vaginal swabs should only be taken when clinically necessary. Women who have had a previous baby infected with GBS are offered intrapartum intravenous benzylpenicillin in future pregnancies.

(Source – RCOG guidelines, GBS in pregnancy).

Group B Streptococcus (GBS) is a common cause of severe infection in newborns. It is estimated that 20-40% of mothers carry GBS in their bowel flora, which can be passed on to their infants during labor and lead to serious infections. Prematurity, prolonged rupture of membranes, previous sibling GBS infection, and maternal pyrexia are all risk factors for GBS infection. The Royal College of Obstetricians and Gynaecologists (RCOG) has published guidelines on GBS management, which include not offering universal screening for GBS to all women and not offering screening based on maternal request. Women who have had GBS detected in a previous pregnancy should be offered intrapartum antibiotic prophylaxis (IAP) or testing in late pregnancy and antibiotics if still positive. IAP should also be offered to women with a previous baby with GBS disease, women in preterm labor, and women with a fever during labor. Benzylpenicillin is the preferred antibiotic for GBS prophylaxis.

Investigations for Male Infertility: Which Tests are Necessary?

Testing for chlamydia is an important part of the initial screening investigations for primary infertility, according to The National Institute for Health and Care Excellence (NICE) guidance. This test should be carried out in primary care prior to referring the couple to secondary care fertility services. On the other hand, screening for gonorrhoea does not form part of these investigations, as it does not tend to affect a patient’s ability to conceive and does not usually remain asymptomatic in affected individuals. Anti-sperm antibodies can be used in secondary care as part of the investigation for couples who are struggling to conceive. However, it would not usually be done in primary care. The NICE guidance on fertility management in men advises that couples who have been trying to conceive after one year of regular intercourse should be referred to fertility services. Watching and waiting would not be appropriate in this situation, as the couple has been trying to conceive for 24 months. Finally, a testicular biopsy is indicated for investigation of potential testicular carcinoma or for sperm retrieval for in-vitro fertilisation procedures. This patient has a normal testicular examination and there is no indication for a testicular biopsy at this point.

Pros and Cons of the Progestogen Only Pill

The progestogen only pill, also known as the mini-pill, is a highly effective form of contraception with a failure rate of only 1 per 100 woman years. One of its advantages is that it does not interfere with sex and its contraceptive effects are reversible upon stopping. It can also be used while breastfeeding and in situations where the combined oral contraceptive pill is contraindicated, such as in smokers over 35 years of age and women with a history of venous thromboembolic disease.

However, the progestogen only pill also has its disadvantages. One of the most common adverse effects is irregular periods, with some users not having periods while others may experience irregular or light periods. It also does not protect against sexually transmitted infections and has an increased incidence of functional ovarian cysts. Common side-effects include breast tenderness, weight gain, acne, and headaches, although these symptoms generally subside after the first few months. Despite its drawbacks, the progestogen only pill remains a popular choice for women seeking a reliable and convenient form of contraception.

Chickenpox exposure in pregnancy can pose risks to both the mother and fetus, including fetal varicella syndrome. Post-exposure prophylaxis (PEP) with varicella-zoster immunoglobulin (VZIG) or antivirals should be given to non-immune pregnant women, with timing dependent on gestational age. If a pregnant woman develops chickenpox, specialist advice should be sought and oral aciclovir may be given if she is ≥ 20 weeks and presents within 24 hours of onset of the rash.

If a pregnant woman is exposed to chickenpox before 20 weeks and has a negative IgG test, it indicates that she is not immune to the virus or has not been previously exposed to it. In such cases, it is recommended to administer varicella-zoster immunoglobulin (VZIG) as soon as possible, which can be effective up to 10 days after exposure. It is not necessary to inform public health as chickenpox is not a notifiable disease.

If a pregnant woman develops a chickenpox rash, VZIG has no therapeutic benefit and should not be used. However, antiviral agents like aciclovir can be given within 24 hours of the rash onset. It is important to note that antiviral agents are recommended for post-exposure prophylaxis for immunosuppressed individuals.

Women who are not immune to varicella-zoster can receive the vaccine before pregnancy or after delivery, but it should not be administered during pregnancy. Therefore, option D cannot be correct in any situation.

Chickenpox exposure in pregnancy can pose risks to both the mother and fetus, including fetal varicella syndrome. Post-exposure prophylaxis (PEP) with varicella-zoster immunoglobulin (VZIG) or antivirals should be given to non-immune pregnant women, with timing dependent on gestational age. If a pregnant woman develops chickenpox, specialist advice should be sought and oral aciclovir may be given if she is ≥ 20 weeks and presents within 24 hours of onset of the rash.

Premature Ovarian Insufficiency: Causes and Management

Premature ovarian insufficiency is a condition where menopausal symptoms and elevated gonadotrophin levels occur before the age of 40. It affects approximately 1 in 100 women and can be caused by various factors such as idiopathic reasons, family history, bilateral oophorectomy, radiotherapy, chemotherapy, infection, autoimmune disorders, and resistant ovary syndrome. The symptoms of premature ovarian insufficiency are similar to those of normal menopause, including hot flushes, night sweats, infertility, secondary amenorrhoea, raised FSH and LH levels, and low oestradiol.

Management of premature ovarian insufficiency involves hormone replacement therapy (HRT) or a combined oral contraceptive pill until the age of the average menopause, which is 51 years. It is important to note that HRT does not provide contraception in case spontaneous ovarian activity resumes. Early diagnosis and management of premature ovarian insufficiency can help alleviate symptoms and improve quality of life for affected women.

Miscarriage is a common complication that can occur in up to 25% of all pregnancies. There are different types of miscarriage, each with its own set of symptoms and characteristics. Threatened miscarriage is painless vaginal bleeding that occurs before 24 weeks, typically at 6-9 weeks. The bleeding is usually less than menstruation, and the cervical os is closed. Missed or delayed miscarriage is when a gestational sac containing a dead fetus is present before 20 weeks, without the symptoms of expulsion. The mother may experience light vaginal bleeding or discharge, and the symptoms of pregnancy may disappear. Pain is not usually a feature, and the cervical os is closed. Inevitable miscarriage is characterized by heavy bleeding with clots and pain, and the cervical os is open. Incomplete miscarriage occurs when not all products of conception have been expelled, and there is pain and vaginal bleeding. The cervical os is open in this type of miscarriage.

Bromocriptine is used to treat galactorrhoea, not to induce it.

Understanding Prolactin and Galactorrhoea

Prolactin is a hormone produced by the anterior pituitary gland, and its release is regulated by various physiological factors. Dopamine is the primary inhibitor of prolactin release, and dopamine agonists like bromocriptine can be used to manage galactorrhoea. Galactorrhoea is a condition characterized by the production of breast milk in individuals who are not breastfeeding. It is important to distinguish the causes of galactorrhoea from those of gynaecomastia, which is the enlargement of male breast tissue.

Excess prolactin can lead to different symptoms in men and women. Men may experience impotence, loss of libido, and galactorrhoea, while women may have amenorrhoea and galactorrhoea. Several factors can cause raised prolactin levels, including prolactinoma, pregnancy, oestrogens, stress, exercise, sleep, acromegaly, polycystic ovarian syndrome, and primary hypothyroidism. Additionally, certain medications like metoclopramide, domperidone, phenothiazines, haloperidol, SSRIs, and opioids can also increase prolactin levels.

In summary, understanding prolactin and its effects on the body is crucial in diagnosing and managing conditions like galactorrhoea. Identifying the underlying causes of raised prolactin levels is essential in providing appropriate treatment and improving patient outcomes.

Breast Masses: Differential Diagnosis and Clinical Features

Breast masses are a common concern for women, and it is important to differentiate between benign and malignant causes. Here, we discuss the clinical features and differential diagnosis of various breast masses.

Diffuse cystic mastopathy is a benign condition that affects a significant proportion of women. It is characterized by the formation of cysts in the breast lobules due to hormonal changes in the menstrual cycle. The lumps are smooth, mobile, and tend to peak in size before each period. Diagnosis is primarily based on clinical examination, but a biopsy may be needed to confirm the diagnosis.

Fat necrosis is another benign condition that can occur due to direct trauma or surgery. It is characterized by the formation of firm, round, and painless masses in the breast. The skin around the lump may be red or bruised, and a biopsy may be needed to differentiate it from breast cancer.

Breast abscesses are characterized by local inflammation, pain, and fever. They may be associated with previous breast infections and may require drainage. However, there is no evidence of an infectious process in this patient.

Breast cancer is a concern in any patient with a breast mass, but early breast cancer is often asymptomatic. Physical findings that may indicate the possible presence of breast cancer include changes in breast size or shape, skin dimpling or changes, nipple abnormalities, and axillary lumps. However, none of these symptoms are present in this patient.

Fibroadenoma is the most common cause of breast mass in women under 35 years of age. It is characterized by a singular, firm, rubbery, smooth, and mobile mass. However, this patient reports multiple lumps, making a diagnosis of fibroadenoma less likely.

In conclusion, the cyclic nature of this patient’s breast masses makes diffuse cystic mastopathy the most likely diagnosis. However, a biopsy may be needed to confirm the diagnosis and rule out other causes.

The prognosis for endometrial cancer is generally favorable.

Endometrial cancer is a type of cancer that is commonly found in women who have gone through menopause, but it can also occur in around 25% of cases before menopause. The prognosis for this type of cancer is usually good due to early detection. There are several risk factors associated with endometrial cancer, including obesity, nulliparity, early menarche, late menopause, unopposed estrogen, diabetes mellitus, tamoxifen, polycystic ovarian syndrome, and hereditary non-polyposis colorectal carcinoma. Postmenopausal bleeding is the most common symptom of endometrial cancer, which is usually slight and intermittent initially before becoming more heavy. Pain is not common and typically signifies extensive disease, while vaginal discharge is unusual.

When investigating endometrial cancer, women who are 55 years or older and present with postmenopausal bleeding should be referred using the suspected cancer pathway. The first-line investigation is trans-vaginal ultrasound, which has a high negative predictive value for a normal endometrial thickness (< 4 mm). Hysteroscopy with endometrial biopsy is also commonly used for investigation. The management of localized disease involves total abdominal hysterectomy with bilateral salpingo-oophorectomy, while patients with high-risk disease may have postoperative radiotherapy. Progestogen therapy is sometimes used in frail elderly women who are not considered suitable for surgery. It is important to note that the combined oral contraceptive pill and smoking are protective against endometrial cancer.

To detect Down’s syndrome, doctors recommend the combined test which involves measuring the thickness of the nuchal translucency during the 12-week scan, as well as conducting blood tests for B-HCG and PAPP-A. This test can only be done between 11 and 13+6 weeks of pregnancy. If the nuchal translucency is thickened, B-HCG levels are high, and PAPP-A levels are low, there is an increased likelihood of Down’s syndrome. The other options listed are incorrect. If a woman misses the window for the combined test, she may be offered the triple or quadruple test between 15-20 weeks, which includes AFP as a marker for Down’s syndrome. Low levels of AFP indicate a higher risk of Down’s syndrome.

NICE updated guidelines on antenatal care in 2021, recommending the combined test for screening for Down’s syndrome between 11-13+6 weeks. The test includes nuchal translucency measurement, serum B-HCG, and pregnancy-associated plasma protein A (PAPP-A). The quadruple test is offered between 15-20 weeks for women who book later in pregnancy. Results are interpreted as either a ‘lower chance’ or ‘higher chance’ of chromosomal abnormalities. If a woman receives a ‘higher chance’ result, she may be offered a non-invasive prenatal screening test (NIPT) or a diagnostic test. NIPT analyzes cell-free fetal DNA in the mother’s blood and has high sensitivity and specificity for detecting chromosomal abnormalities. Private companies offer NIPT screening from 10 weeks gestation.

For the treatment of genital warts, topical podophyllum is recommended for multiple, non-keratinised warts, while cryotherapy is recommended for solitary, keratinised warts. Cryotherapy can also be used as an initial treatment for genital warts.

Understanding Genital Warts

Genital warts, also known as condylomata accuminata, are a common reason for visits to genitourinary clinics. These warts are caused by various types of the human papillomavirus (HPV), with types 6 and 11 being the most common culprits. It is important to note that HPV, particularly types 16, 18, and 33, can increase the risk of cervical cancer.

The warts themselves are small, fleshy protrusions that are typically 2-5mm in size and may be slightly pigmented. They can cause discomfort, itching, and even bleeding. Treatment options for genital warts include topical podophyllum or cryotherapy, depending on the location and type of lesion. Topical agents are generally used for multiple, non-keratinised warts, while solitary, keratinised warts respond better to cryotherapy. Imiquimod, a topical cream, is often used as a second-line treatment. It is important to note that genital warts can be resistant to treatment, and recurrence is common. However, most anogenital HPV infections clear up on their own within 1-2 years without intervention.

Breast cancer is the second most common cancer in women and the leading cause of cancer death among women worldwide. Tamoxifen is a drug that can be used to treat breast cancer that requires estrogen to grow. It works by either blocking estrogen receptors or blocking the production of estrogen. For women with estrogen receptor-positive breast cancer, continuing tamoxifen for 10 years instead of stopping at 5 years can further reduce the risk of recurrence and mortality. However, tamoxifen does not affect the risk of breast cancer recurrence. The risk of endometrial cancer is slightly increased with tamoxifen treatment. Screening modalities include breast self-examination, clinical breast examination, mammography, ultrasonography, and magnetic resonance imaging. Early detection is crucial in preventing breast cancer, and screening intervals may need to be shortened to prevent more deaths. Physical examination and biopsy are also important diagnostic approaches. Treatment for breast cancer typically involves surgery, radiation therapy, and adjuvant hormone or chemotherapy when necessary.

When a pregnant woman experiences vaginal bleeding in the third trimester, it is important to promptly assess her and focus on her and the fetus’s well-being. This includes monitoring vital signs, initiating electronic fetal monitoring, and obtaining blood tests to determine the need for Rh immunoglobulin and blood transfusions. If significant bleeding occurs, blood should be cross-matched for rapid replacement of blood volume. Once stability is achieved, the cause of the bleeding can be assessed through ultrasound and sterile speculum exams. If the bleeding is severe or fetal monitoring is non-reassuring, emergency caesarean delivery is necessary. Otherwise, the mode of delivery is determined by the proximity of the placenta to the internal os of the cervix. Hospitalization is recommended for at least 48 hours during a sentinel bleeding episode, and multiple episodes may require hospitalization until delivery. Disseminated intravascular coagulation should also be considered, and clotting studies may be ordered. this patient should be admitted and aim for elective caesarean section at 39 weeks
Respiratory morbidity, including transient tachypnoea of the newborn (TTN), is more common in babies delivered by caesarean section, especially before 39 weeks.

When managing an ectopic pregnancy through surgery, it is necessary to administer Anti-D immunoglobulin. However, if the ectopic pregnancy is being treated medically or if the location of the pregnancy is unknown, Anti-D is not needed. The Coombs test has two types: Direct Coombs, which is used to detect autoimmune haemolytic anaemia, and Indirect Coombs, which is used during pregnancy to identify antibodies in the mother’s blood that can cause haemolytic disease in the newborn.

Rhesus negative pregnancies can lead to the formation of anti-D IgG antibodies in the mother if she delivers a Rh +ve child, which can cause haemolysis in future pregnancies. Prevention involves testing for D antibodies and giving anti-D prophylaxis to non-sensitised Rh -ve mothers at 28 and 34 weeks. Anti-D immunoglobulin should be given within 72 hours in various situations. Tests should be done on all babies born to Rh -ve mothers, and affected fetuses may experience various complications and require treatment such as transfusions and UV phototherapy.

Having endometriosis increases the risk of experiencing an ectopic pregnancy. This patient’s symptoms and positive pregnancy test suggest a likely diagnosis of an ectopic pregnancy. Other risk factors for ectopic pregnancy include previous ectopic pregnancy, fallopian tube damage, and IVF. However, multiparity, previous pre-eclampsia, twin pregnancy, and type 2 diabetes mellitus are not associated with an increased risk of ectopic pregnancy.

Understanding Ectopic Pregnancy: Incidence and Risk Factors

Ectopic pregnancy occurs when a fertilized egg implants outside the uterus, usually in the fallopian tubes. This condition is a serious medical emergency that requires immediate attention. According to epidemiological studies, ectopic pregnancy occurs in approximately 0.5% of all pregnancies.

Several risk factors can increase the likelihood of ectopic pregnancy. These include damage to the fallopian tubes due to pelvic inflammatory disease or surgery, a history of previous ectopic pregnancy, endometriosis, the use of intrauterine contraceptive devices (IUCDs), and the progesterone-only pill. In vitro fertilization (IVF) also increases the risk of ectopic pregnancy, with approximately 3% of IVF pregnancies resulting in ectopic implantation.

It is important to note that any factor that slows down the passage of the fertilized egg to the uterus can increase the risk of ectopic pregnancy. Early detection and prompt treatment are crucial in managing this condition and preventing serious complications.

Bacterial vaginosis is a condition characterized by the excessive growth of mainly bacteria.

Bacterial vaginosis (BV) is a condition where there is an overgrowth of anaerobic organisms, particularly Gardnerella vaginalis, in the vagina. This leads to a decrease in the amount of lactobacilli, which produce lactic acid, resulting in an increase in vaginal pH. BV is not a sexually transmitted infection, but it is commonly seen in sexually active women. Symptoms include a fishy-smelling vaginal discharge, although some women may not experience any symptoms at all. Diagnosis is made using Amsel’s criteria, which includes the presence of thin, white discharge, clue cells on microscopy, a vaginal pH greater than 4.5, and a positive whiff test. Treatment involves oral metronidazole for 5-7 days, with a cure rate of 70-80%. However, relapse rates are high, with over 50% of women experiencing a recurrence within 3 months. Topical metronidazole or clindamycin may be used as alternatives.

Bacterial vaginosis during pregnancy can increase the risk of preterm labor, low birth weight, chorioamnionitis, and late miscarriage. It was previously recommended to avoid oral metronidazole in the first trimester and use topical clindamycin instead. However, recent guidelines suggest that oral metronidazole can be used throughout pregnancy. The British National Formulary (BNF) still advises against using high-dose metronidazole regimes. Clue cells, which are vaginal epithelial cells covered with bacteria, can be seen on microscopy in women with BV.

If a woman on COCP misses one pill, she should take the missed pill immediately and then take the next pill at the usual time. There is no need for any further action or emergency contraception such as a copper IUD. She can continue with the 7-day pill-free break as normal. Discarding the missed pill is not recommended as it could increase the risk of an unwanted pregnancy. Starting the next pack without the 7-day break is also not necessary in this case. However, if she misses two pills and there are fewer than seven pills left in the pack, she would need to start the next pack without a break.

Missed Pills in Combined Oral Contraceptive Pill

When taking a combined oral contraceptive (COC) pill containing 30-35 micrograms of ethinylestradiol, it is important to know what to do if a pill is missed. The Faculty of Sexual and Reproductive Healthcare (FSRH) has updated their recommendations in recent years. If one pill is missed at any time in the cycle, the woman should take the last pill even if it means taking two pills in one day and then continue taking pills daily, one each day. No additional contraceptive protection is needed in this case.

However, if two or more pills are missed, the woman should take the last pill even if it means taking two pills in one day, leave any earlier missed pills, and then continue taking pills daily, one each day. In this case, the woman should use condoms or abstain from sex until she has taken pills for 7 days in a row. If pills are missed in week 1 (Days 1-7), emergency contraception should be considered if she had unprotected sex in the pill-free interval or in week 1. If pills are missed in week 2 (Days 8-14), after seven consecutive days of taking the COC there is no need for emergency contraception.

If pills are missed in week 3 (Days 15-21), the woman should finish the pills in her current pack and start a new pack the next day, thus omitting the pill-free interval. Theoretically, women would be protected if they took the COC in a pattern of 7 days on, 7 days off. It is important to follow these guidelines to ensure the effectiveness of the COC in preventing pregnancy.

To confirm or rule out ectopic pregnancy, the recommended investigation is transvaginal ultrasound. This is because it provides clearer images of the uterus, ovaries, and endometrium, making it more effective in detecting ectopic pregnancies compared to transabdominal scans. While serum Beta-HCG levels are helpful in managing ectopic pregnancies, a single test cannot completely rule out the possibility. Pregnant women are generally advised against undergoing CT scans and abdominal X-rays.

Ectopic pregnancy is a serious condition that requires prompt investigation and management. Women who are stable are typically investigated and managed in an early pregnancy assessment unit, while those who are unstable should be referred to the emergency department. The investigation of choice for ectopic pregnancy is a transvaginal ultrasound, which will confirm the presence of a positive pregnancy test.

There are three ways to manage ectopic pregnancies: expectant management, medical management, and surgical management. The choice of management will depend on various criteria, such as the size of the ectopic pregnancy, whether it is ruptured or not, and the patient’s symptoms and hCG levels. Expectant management involves closely monitoring the patient over 48 hours, while medical management involves giving the patient methotrexate and requires follow-up. Surgical management can involve salpingectomy or salpingotomy, depending on the patient’s risk factors for infertility.

Salpingectomy is the first-line treatment for women with no other risk factors for infertility, while salpingotomy should be considered for women with contralateral tube damage. However, around 1 in 5 women who undergo a salpingotomy require further treatment, such as methotrexate and/or a salpingectomy. It is important to carefully consider the patient’s individual circumstances and make a decision that will provide the best possible outcome.

To confirm ovulation in patients struggling to conceive, a serum progesterone level should be taken 7 days prior to the expected next period. This timing coincides with ovulation and is the most accurate way to confirm it. Taking the test 14 days before the next expected period or on the first day of the next period would not be timed correctly. It is also important to note that the timing of intercourse does not affect the confirmation of ovulation through serum progesterone testing.

Infertility is a common issue that affects approximately 1 in 7 couples. It is important to note that around 84% of couples who have regular sexual intercourse will conceive within the first year, and 92% within the first two years. The causes of infertility can vary, with male factor accounting for 30%, unexplained causes accounting for 20%, ovulation failure accounting for 20%, tubal damage accounting for 15%, and other causes accounting for the remaining 15%.

When investigating infertility, there are some basic tests that can be done. These include a semen analysis and a serum progesterone test. The serum progesterone test is done 7 days prior to the expected next period, typically on day 21 for a 28-day cycle. The interpretation of the serum progesterone level is as follows: if it is less than 16 nmol/l, it should be repeated and if it remains consistently low, referral to a specialist is necessary. If the level is between 16-30 nmol/l, it should be repeated, and if it is greater than 30 nmol/l, it indicates ovulation.

It is important to counsel patients on lifestyle factors that can impact fertility. This includes taking folic acid, maintaining a healthy BMI between 20-25, and advising regular sexual intercourse every 2 to 3 days. Additionally, patients should be advised to quit smoking and limit alcohol consumption to increase their chances of conceiving.

There are several methods for screening and diagnosing Down’s syndrome in pregnancy. The nuchal translucency scan, which measures fluid in the fetal neck, is best done between 11 and 14 weeks and can detect an increased risk of genetic syndromes. The triple screen, which measures levels of certain hormones in the mother’s blood, is done in the second trimester and can detect up to 69% of cases in singleton pregnancies, but may have a higher false positive or false negative in twin pregnancies. Amniocentesis and chorionic villous sampling are invasive diagnostic tests that can detect chromosomal disorders with high accuracy, but carry a small risk of pregnancy loss. The routine anomaly scan should not be used for Down’s syndrome screening. Cell-free fetal DNA screening is a newer method that can detect about 99% of Down’s syndrome pregnancies, but is currently only offered by private clinics at a high cost. A positive screening result suggests an increased risk for Down’s syndrome, and definitive testing with chorionic villous sampling or amniocentesis is indicated.

If a pregnant woman is not immune to the varicella zoster virus and has been in close contact with someone who has the virus, it is recommended that she receive varicella-zoster immunoglobulin (VZIG) as soon as possible. VZIG can be effective up to 10 days after contact, or 10 days after the appearance of the rash in the person with the virus if there are continuous exposures.
For pregnant women who are not immune and have been exposed to chickenpox, they should be considered potentially infectious from 8-28 days after exposure if they receive VZIG, and from 8-21 days after exposure if they do not receive VZIG.
Source: RCOG

Chickenpox exposure in pregnancy can pose risks to both the mother and fetus, including fetal varicella syndrome. Post-exposure prophylaxis (PEP) with varicella-zoster immunoglobulin (VZIG) or antivirals should be given to non-immune pregnant women, with timing dependent on gestational age. If a pregnant woman develops chickenpox, specialist advice should be sought and oral aciclovir may be given if she is ≥ 20 weeks and presents within 24 hours of onset of the rash.

When it comes to treating prolactinomas, dopamine agonists like cabergoline and bromocriptine are typically the first choice, even if the patient is experiencing significant neurological complications. Surgery may be necessary for those who cannot tolerate or do not respond to medical treatment, with a trans-sphenoidal approach being the preferred method unless there is extensive extra-pituitary extension. Radiotherapy is not commonly used, and octreotide, a somatostatin analogue, is primarily used to treat acromegaly.

Understanding Prolactinoma: A Type of Pituitary Adenoma

Prolactinoma is a type of pituitary adenoma, which is a non-cancerous tumor that develops in the pituitary gland. These tumors can be classified based on their size and hormonal status. Prolactinomas are the most common type of pituitary adenoma and are characterized by the overproduction of prolactin. This condition can cause a range of symptoms in both men and women.

In women, excess prolactin can lead to amenorrhea, infertility, and galactorrhea. Men with prolactinoma may experience impotence, loss of libido, and galactorrhea. Macroadenomas, which are larger tumors, can cause additional symptoms such as headaches, visual disturbances, and signs of hypopituitarism.

Diagnosis of prolactinoma is typically done through MRI imaging. Treatment for symptomatic patients usually involves the use of dopamine agonists, such as cabergoline or bromocriptine, which help to inhibit the release of prolactin from the pituitary gland. In cases where medical therapy is not effective or well-tolerated, surgery may be necessary. A trans-sphenoidal approach is often preferred for surgical intervention, unless there is significant extra-pituitary extension.

Overall, understanding prolactinoma and its symptoms is important for early diagnosis and effective management of this condition.

Understanding Cervical Cancer and Abnormal Smear Test Results

Cervical cancer is a common malignancy in women worldwide and can be detected through routine cervical screening. An abnormal Papanicolaou (‘smear’) test result is the most common finding in patients with cervical cancer. Physical symptoms may include abnormal vaginal bleeding, vaginal discomfort, malodorous discharge, and dysuria. Referral for colposcopy and biopsy should be made within two weeks for patients with symptoms of cervical cancer. Women with a cervical cytology result of moderate, high-grade dyskaryosis, suspected invasive cancer or glandular neoplasia should also be referred for colposcopy within two weeks. Cervical cauterisation with silver nitrate is not associated with the development of cervical cancer and is used to treat cervical ectropion. Endocervical swab for Chlamydia spp. may be necessary for women presenting with mucopurulent cervicitis. Understanding these guidelines and symptoms can help with early detection and treatment of cervical cancer.

It is essential to treat the candidal infection by administering miconazole cream to both the mother and child. The cream should be applied to the nipple after feeding and the infant’s oral mucosa. Breastfeeding should continue during the treatment period. Additionally, the mother should be educated on maintaining good hand hygiene after changing the baby’s nappy and sterilizing any objects that the baby puts in their mouth, such as dummies and teats. This information is provided by NICE CKS.

Breastfeeding Problems and Their Management

Breastfeeding is a natural process, but it can come with its own set of challenges. Some of the minor problems that breastfeeding mothers may encounter include frequent feeding, nipple pain, blocked ducts, and nipple candidiasis. These issues can be managed by seeking advice on proper positioning, trying breast massage, and using appropriate medication.

Mastitis is a more serious problem that affects around 1 in 10 breastfeeding women. It is characterized by symptoms such as fever, nipple fissure, and persistent pain. Treatment involves the use of antibiotics, such as flucloxacillin, for 10-14 days. Breastfeeding or expressing milk should continue during treatment to prevent complications such as breast abscess.

Breast engorgement is another common problem that causes breast pain in breastfeeding women. It occurs in the first few days after birth and affects both breasts. Hand expression of milk can help relieve the discomfort of engorgement. Raynaud’s disease of the nipple is a less common problem that causes nipple pain and blanching. Treatment involves minimizing exposure to cold, using heat packs, and avoiding caffeine and smoking.

If a breastfed baby loses more than 10% of their birth weight in the first week of life, it may be a sign of poor weight gain. This should prompt consideration of the above breastfeeding problems and an expert review of feeding. Monitoring of weight should continue until weight gain is satisfactory.

To determine the cause of the watery vaginal discharge in this patient, further information about her sexual history would be necessary. However, based on the appearance of her cervix, a diagnosis of Gonorrhoea is unlikely. Gonorrhoea typically presents with a green and purulent discharge, and is not often associated with an odour. Similarly, Chlamydia would likely cause more problems with the cervix and a more mucopurulent discharge. Herpes simplex does not typically cause vaginal discharge, but instead presents with ulcers or tingling sensations around the vulva. Thrush, or candidiasis, would likely cause more itching and have a thicker, cottage cheese-like consistency. Bacterial vaginosis is the most likely diagnosis, as it often presents with a fishy odour and a thin, watery discharge that may be green or white. It can be asymptomatic and does not typically cause irritation or soreness. Diagnosis can be confirmed with a vaginal pH > 4.5 and the presence of clue cells on microscopy. These findings are in line with BASHH guidelines.

Bacterial vaginosis (BV) is a condition where there is an overgrowth of anaerobic organisms, particularly Gardnerella vaginalis, in the vagina. This leads to a decrease in the amount of lactobacilli, which produce lactic acid, resulting in an increase in vaginal pH. BV is not a sexually transmitted infection, but it is commonly seen in sexually active women. Symptoms include a fishy-smelling vaginal discharge, although some women may not experience any symptoms at all. Diagnosis is made using Amsel’s criteria, which includes the presence of thin, white discharge, clue cells on microscopy, a vaginal pH greater than 4.5, and a positive whiff test. Treatment involves oral metronidazole for 5-7 days, with a cure rate of 70-80%. However, relapse rates are high, with over 50% of women experiencing a recurrence within 3 months. Topical metronidazole or clindamycin may be used as alternatives.

Bacterial vaginosis during pregnancy can increase the risk of preterm labor, low birth weight, chorioamnionitis, and late miscarriage. It was previously recommended to avoid oral metronidazole in the first trimester and use topical clindamycin instead. However, recent guidelines suggest that oral metronidazole can be used throughout pregnancy. The British National Formulary (BNF) still advises against using high-dose metronidazole regimes. Clue cells, which are vaginal epithelial cells covered with bacteria, can be seen on microscopy in women with BV.

Hormone replacement therapy (HRT) is a treatment that involves administering synthetic oestrogen and progestogen to women experiencing menopausal symptoms. HRT can be given as local (creams, pessaries, rings) or systemic therapy (oral drugs, transdermal patches and gels, implants) and may contain oestrogen alone, combined oestrogen and progestogen, selective oestrogen receptor modulator, or gonadomimetics. The average age for menopause is around 50-51 years, and symptoms include hot flushes, insomnia, weight gain, mood changes, and irregular menses. HRT should be initiated at the lowest possible dosage and titrated based on clinical response. However, HRT is not recommended for women who have undergone hysterectomy due to the risk of endometrial hyperplasia, a precursor to endometrial cancer. HRT may also increase the risk of breast cancer and heart attacks, and non-hormonal options should be considered for menopausal effects in women who have previously had breast cancer. There is no evidence to suggest that HRT is associated with an increased or decreased risk of developing cervical cancer, and observational studies of systemic HRT after breast cancer are generally reassuring. Oestrogen is believed to be a growth factor that enhances cholinergic neurotransmission and prevents oxidative cell damage, neuronal atrophy, and glucocorticoid-induced neuronal damage, which may help prevent dementia.

Understanding Chorioamnionitis

Chorioamnionitis is a serious medical condition that can affect both the mother and the foetus during pregnancy. It is caused by a bacterial infection that affects the amniotic fluid, membranes, and placenta. This condition is considered a medical emergency and can be life-threatening if not treated promptly. It is more likely to occur when the membranes rupture prematurely, but it can also happen when the membranes are still intact.

Prompt delivery of the foetus is crucial in treating chorioamnionitis, and a cesarean section may be necessary. Intravenous antibiotics are also administered to help fight the infection. This condition affects up to 5% of all pregnancies, and it is important for pregnant women to be aware of the symptoms and seek medical attention immediately if they suspect they may have chorioamnionitis.

GnRH agonists can be effective in reducing the size of uterine fibroids, but their use is typically limited to short-term treatment. It is important to note that these agonists are primarily used to decrease the size of the uterus prior to surgery, as the risk of post-operative blood loss is directly related to the size of the uterus. Progesterone receptor inhibitors, on the other hand, do not have an impact on overall uterine size and are therefore not useful in preparing for surgery. However, they can be helpful in reducing the severity of fibroid-related bleeding. It is also important to avoid taking COCP 4-6 weeks prior to major surgery due to an increased risk of venous thromboembolism, and to avoid antiplatelet drugs such as Ibuprofen before surgery. While antifibrinolytics like tranexamic acid can be useful in reducing the severity of uterine bleeding, they are not helpful in preparing for surgery.

Understanding Uterine Fibroids

Uterine fibroids are non-cancerous growths that develop in the uterus. They are more common in black women and are thought to occur in around 20% of white women in their later reproductive years. Fibroids are usually asymptomatic, but they can cause menorrhagia, which can lead to iron-deficiency anaemia. Other symptoms include lower abdominal pain, bloating, and urinary symptoms. Fibroids may also cause subfertility.

Diagnosis is usually made through transvaginal ultrasound. Asymptomatic fibroids do not require treatment, but periodic monitoring is recommended. Menorrhagia secondary to fibroids can be managed with various treatments, including the levonorgestrel intrauterine system, NSAIDs, tranexamic acid, and hormonal therapies.

Medical treatment to shrink or remove fibroids may include GnRH agonists or ulipristal acetate, although the latter is not currently recommended due to concerns about liver toxicity. Surgical options include myomectomy, hysteroscopic endometrial ablation, hysterectomy, and uterine artery embolization.

Fibroids generally regress after menopause, but complications such as subfertility and iron-deficiency anaemia can occur. Red degeneration, which is haemorrhage into the tumour, is a common complication during pregnancy.

The copper intrauterine device is the recommended form of contraception for individuals with breast cancer. Hormonal forms of contraception are not recommended and are rated as a Category 4 risk, which is deemed unacceptable for the patient’s health.

The decision to prescribe the combined oral contraceptive pill is now based on the UK Medical Eligibility Criteria (UKMEC), which categorizes potential contraindications and cautions on a four-point scale. UKMEC 1 indicates no restrictions for use, while UKMEC 2 suggests that the benefits outweigh the risks. UKMEC 3 indicates that the disadvantages may outweigh the advantages, and UKMEC 4 represents an unacceptable health risk. Examples of UKMEC 3 conditions include controlled hypertension, a family history of thromboembolic disease in first-degree relatives under 45 years old, and current gallbladder disease. Examples of UKMEC 4 conditions include a history of thromboembolic disease or thrombogenic mutation, breast cancer, and uncontrolled hypertension. Diabetes mellitus diagnosed over 20 years ago is classified as UKMEC 3 or 4 depending on severity. In 2016, breast feeding between 6 weeks and 6 months postpartum was changed from UKMEC 3 to UKMEC 2.

Hypertension during pregnancy is a common occurrence that requires careful management. In normal pregnancies, blood pressure tends to decrease in the first trimester and then gradually increase to pre-pregnancy levels by term. However, in cases of hypertension during pregnancy, the systolic blood pressure is usually above 140 mmHg or the diastolic blood pressure is above 90 mmHg. Additionally, an increase of more than 30 mmHg systolic or 15 mmHg diastolic from the initial readings may also indicate hypertension.

There are three categories of hypertension during pregnancy: pre-existing hypertension, pregnancy-induced hypertension (PIH), and pre-eclampsia. Pre-existing hypertension refers to a history of hypertension before pregnancy or elevated blood pressure before 20 weeks gestation. PIH occurs in the second half of pregnancy and resolves after birth. Pre-eclampsia is characterized by hypertension and proteinuria, and may also involve edema.

The management of hypertension during pregnancy involves the use of antihypertensive medications such as labetalol, nifedipine, and hydralazine. In cases of pre-existing hypertension, ACE inhibitors and angiotensin II receptor blockers should be stopped immediately and alternative medications should be prescribed. Women who are at high risk of developing pre-eclampsia should take aspirin from 12 weeks until the birth of the baby. It is important to carefully monitor blood pressure and proteinuria levels during pregnancy to ensure the health of both the mother and the baby.

Taking metronidazole and alcohol together can result in a disulfiram-like reaction, so patients should be cautioned against consuming alcohol while on the medication. Metronidazole is not associated with cholestasis, hepatotoxicity, or QT prolongation. As an enzyme inhibitor, metronidazole enhances the efficacy of the COCP. While Stevens-Johnson syndrome is a rare side effect of metronidazole, a photosensitive rash is not typically observed.

Metronidazole is an antibiotic that functions by producing reactive cytotoxic metabolites within bacteria. This medication can cause adverse effects such as a disulfiram-like reaction when combined with alcohol and an increased anticoagulant effect when taken with warfarin.

Understanding Vulval Carcinoma

Vulval carcinoma is a type of cancer that affects the vulva, which is the external female genitalia. It is a relatively rare condition, with only around 1,200 cases diagnosed in the UK each year. The majority of cases occur in women over the age of 65 years, and around 80% of cases are squamous cell carcinomas.

There are several risk factors associated with vulval carcinoma, including human papilloma virus (HPV) infection, vulval intraepithelial neoplasia (VIN), immunosuppression, and lichen sclerosus. Symptoms of vulval carcinoma may include a lump or ulcer on the labia majora, inguinal lymphadenopathy, and itching or irritation.

It is important for women to be aware of the risk factors and symptoms of vulval carcinoma, and to seek medical attention if they experience any concerning symptoms. Early detection and treatment can improve outcomes and increase the chances of a full recovery.

For pregnant women who are at moderate or high risk of pre-eclampsia, it is recommended to take aspirin in low doses of 75-150mg daily from 12 weeks of gestation until delivery. In this case, the patient has three moderate risk factors for pre-eclampsia and should be advised to take low-dose aspirin throughout her pregnancy. While hydralazine is an alternative antihypertensive medication to labetalol in pregnancy, it is not necessary for this patient as she is not hypertensive. Labetalol is the first-line antihypertensive medication for pregnant women. Magnesium is only indicated for severe pre-eclampsia to prevent or treat seizures in patients with eclampsia, which is not present in this patient.

Pre-eclampsia is a condition that occurs during pregnancy and is characterized by high blood pressure, proteinuria, and edema. It can lead to complications such as eclampsia, neurological issues, fetal growth problems, liver involvement, and cardiac failure. Severe pre-eclampsia is marked by hypertension, proteinuria, headache, visual disturbances, and other symptoms. Risk factors for pre-eclampsia include hypertension in a previous pregnancy, chronic kidney disease, autoimmune disease, diabetes, chronic hypertension, first pregnancy, and age over 40. Aspirin may be recommended for women with high or moderate risk factors. Treatment involves emergency assessment, admission for observation, and medication such as labetalol, nifedipine, or hydralazine. Delivery of the baby is the most important step in management, with timing depending on the individual case.

According to NICE guidelines, non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, naproxen, or mefenamic acid should be the first-line treatment for primary dysmenorrhoea, unless contraindicated. Combined oral contraceptives (COCs) containing ethinylestradiol and norethisterone, norgestimate, or levonorgestrel are also recommended for women who do not wish to conceive. However, for a non-sexually active woman, a non-hormonal drug would be more appropriate. Paracetamol can be prescribed if NSAIDs are not tolerated or contraindicated. Tranexamic acid is useful for menorrhagia, not dysmenorrhoea. The diagnosis of primary dysmenorrhoea is likely if menstrual pain starts 6-12 months after menarche, before menstruation, and lasts up to 72 hours, with non-gynaecological symptoms present, and a normal pelvic examination.

The human papillomavirus (HPV) is a common sexually transmitted infection that can lead to cervical cancer. There are over 100 types of HPV, with types 16 and 18 being high-risk types that are responsible for the majority of cervical cancers. Types 6 and 11 are low-risk types that typically cause benign genital warts. Although not part of the screening process, the Gardasil vaccine can protect against both HPV types 6 and 11.

Contrary to popular belief, not all samples undergo both HPV testing and cytology. Only samples that test positive for high-risk HPV undergo cytology testing. Samples that test negative for high-risk HPV do not require further testing.

In the past, samples were first examined under a microscope (cytology) before HPV testing. However, research has shown that testing for high-risk HPV first is more effective. If a woman tests positive for HPV, she will receive a single letter informing her of her HPV status and whether any abnormal cells were detected.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

For patients experiencing recurrent vaginal candidiasis, it is recommended to consider an induction-maintenance regime of oral fluconazole. Over the counter antifungal treatments, such as clotrimazole cream, are typically effective for one-off episodes of thrush. However, in cases of recurrent symptoms, a more comprehensive treatment plan may be necessary. It is important to ensure that the patient is not taking SSRI medications or has hypersensitivity to ‘azole’ antifungal medications before prescribing fluconazole. It should be noted that IM ceftriaxone and oral ciprofloxacin are used to manage Neisseria gonorrhoea, not thrush, and oral metronidazole is used to manage bacterial vaginosis, not thrush.

Vaginal candidiasis, also known as thrush, is a common condition that many women can diagnose and treat themselves. Candida albicans is responsible for about 80% of cases, while other candida species cause the remaining 20%. Although most women have no predisposing factors, certain factors such as diabetes mellitus, antibiotics, steroids, pregnancy, and HIV can increase the likelihood of developing vaginal candidiasis. Symptoms include non-offensive discharge resembling cottage cheese, vulvitis, itching, vulval erythema, fissuring, and satellite lesions. A high vaginal swab is not routinely indicated if the clinical features are consistent with candidiasis. Treatment options include local or oral therapy, with oral fluconazole 150 mg as a single dose being the first-line treatment according to NICE Clinical Knowledge Summaries. If there are vulval symptoms, a topical imidazole may be added to an oral or intravaginal antifungal. Pregnant women should only use local treatments. Recurrent vaginal candidiasis is defined as four or more episodes per year by BASHH. Compliance with previous treatment should be checked, and a high vaginal swab for microscopy and culture should be performed to confirm the diagnosis. A blood glucose test may be necessary to exclude diabetes, and differential diagnoses such as lichen sclerosus should be ruled out. An induction-maintenance regime involving oral fluconazole may be considered. Induction involves taking oral fluconazole every three days for three doses, while maintenance involves taking oral fluconazole weekly for six months.

Maternal obesity with a BMI of 30 kg/m2 or more increases the risk of neural tube defects in babies. There is no strong evidence linking obesity to hyper- or hypothyroidism in neonates, an increased risk of Down syndrome, or cystic fibrosis.

Folic Acid: Importance, Deficiency, and Prevention

Folic acid is a vital nutrient that is converted to tetrahydrofolate (THF) in the body. It is found in green, leafy vegetables and plays a crucial role in the transfer of 1-carbon units to essential substrates involved in the synthesis of DNA and RNA. However, certain factors such as phenytoin, methotrexate, pregnancy, and alcohol excess can cause a deficiency in folic acid. This deficiency can lead to macrocytic, megaloblastic anemia and neural tube defects.

To prevent neural tube defects during pregnancy, it is recommended that all women take 400mcg of folic acid until the 12th week of pregnancy. Women at higher risk of conceiving a child with a neural tube defect should take 5mg of folic acid from before conception until the 12th week of pregnancy. Women are considered higher risk if they or their partner has a neural tube defect, they have had a previous pregnancy affected by a neural tube defect, or they have a family history of a neural tube defect. Additionally, women with certain medical conditions such as coeliac disease, diabetes, or thalassaemia trait, or those taking antiepileptic drugs, or who are obese (BMI of 30 kg/m2 or more) are also considered higher risk.

In summary, folic acid is an essential nutrient that plays a crucial role in DNA and RNA synthesis. Deficiency in folic acid can lead to serious health consequences, including neural tube defects. However, taking folic acid supplements during pregnancy can prevent these defects and ensure a healthy pregnancy.

Starting September 2019, boys in school Year 8 who are 12-13 years old will also be provided with the HPV vaccine, which is currently administered in two doses. Girls receive the second dose within 6-24 months after the first, depending on local guidelines.

The human papillomavirus (HPV) is a known carcinogen that infects the skin and mucous membranes. There are numerous strains of HPV, with the most significant being 6 & 11, which cause genital warts, and 16 & 18, which are linked to various cancers, particularly cervical cancer. HPV infection is responsible for over 99.7% of cervical cancers, and testing for HPV is now a crucial part of cervical cancer screening. Other cancers linked to HPV include anal, vulval, vaginal, mouth, and throat cancers. While there are other risk factors for cervical cancer, such as smoking and contraceptive pill use, HPV is a significant contributor.

In 2008, the UK introduced a vaccination for HPV, initially using Cervarix, which protected against HPV 16 & 18 but not 6 & 11. This decision was criticized due to the significant disease burden caused by genital warts. In 2012, Gardasil replaced Cervarix as the vaccine used, protecting against HPV 6, 11, 16 & 18. Initially given only to girls, boys were also offered the vaccine from September 2019. All 12- and 13-year-olds in school Year 8 are offered the HPV vaccine, which is typically given in school. Parents are informed that their daughter may receive the vaccine against their wishes. The vaccine is given in two doses, with the second dose administered between 6-24 months after the first, depending on local policy. Men who have sex with men under the age of 45 should also be offered the HPV vaccine to protect against anal, throat, and penile cancers. Injection site reactions are common with HPV vaccines.

Bacterial vaginosis (BV) is a common vaginal infection that affects many women, with up to 50% of cases being asymptomatic. The main symptom of BV is a fishy-smelling discharge from the vagina.

In pregnant women, BV can lead to late miscarriage and preterm delivery if left untreated. Therefore, all pregnant women who experience symptoms should receive treatment. This typically involves taking oral metronidazole twice a day for 5-7 days, as a single 2-gram dose is not recommended during pregnancy.

However, for asymptomatic pregnant women with BV, treatment is considered on a case-by-case basis. This is because research suggests that identifying and treating asymptomatic cases does not necessarily reduce the risk of preterm birth. This information is based on guidelines from NICE CKS.

Bacterial vaginosis (BV) is a condition where there is an overgrowth of anaerobic organisms, particularly Gardnerella vaginalis, in the vagina. This leads to a decrease in the amount of lactobacilli, which produce lactic acid, resulting in an increase in vaginal pH. BV is not a sexually transmitted infection, but it is commonly seen in sexually active women. Symptoms include a fishy-smelling vaginal discharge, although some women may not experience any symptoms at all. Diagnosis is made using Amsel’s criteria, which includes the presence of thin, white discharge, clue cells on microscopy, a vaginal pH greater than 4.5, and a positive whiff test. Treatment involves oral metronidazole for 5-7 days, with a cure rate of 70-80%. However, relapse rates are high, with over 50% of women experiencing a recurrence within 3 months. Topical metronidazole or clindamycin may be used as alternatives.

Bacterial vaginosis during pregnancy can increase the risk of preterm labor, low birth weight, chorioamnionitis, and late miscarriage. It was previously recommended to avoid oral metronidazole in the first trimester and use topical clindamycin instead. However, recent guidelines suggest that oral metronidazole can be used throughout pregnancy. The British National Formulary (BNF) still advises against using high-dose metronidazole regimes. Clue cells, which are vaginal epithelial cells covered with bacteria, can be seen on microscopy in women with BV.

Women with a higher chance of Down’s syndrome based on combined or quadruple tests are offered further screening or diagnostic tests. In this case, the patient’s chance is 1 in 100, making non-invasive prenatal screening (NIPT) the most appropriate option. Amniocentesis and chorionic villous sampling (CVS) are less appropriate due to their invasive nature and higher risks.

NICE updated guidelines on antenatal care in 2021, recommending the combined test for screening for Down’s syndrome between 11-13+6 weeks. The test includes nuchal translucency measurement, serum B-HCG, and pregnancy-associated plasma protein A (PAPP-A). The quadruple test is offered between 15-20 weeks for women who book later in pregnancy. Results are interpreted as either a ‘lower chance’ or ‘higher chance’ of chromosomal abnormalities. If a woman receives a ‘higher chance’ result, she may be offered a non-invasive prenatal screening test (NIPT) or a diagnostic test. NIPT analyzes cell-free fetal DNA in the mother’s blood and has high sensitivity and specificity for detecting chromosomal abnormalities. Private companies offer NIPT screening from 10 weeks gestation.

Differential Diagnosis: Abdominal Swelling and Tenderness in a Female Patient

Ovarian carcinoma is the most likely diagnosis for a female patient presenting with abdominal swelling and tenderness. This type of cancer is the leading cause of gynecological cancer deaths in developed countries, with a higher incidence in women over 55 years of age and those with a family history of breast or ovarian cancer. Imaging studies, such as ultrasonography, CT, and MRI, can aid in diagnosis, along with elevated levels of Ca-125. Surgery is often the initial treatment, followed by chemotherapy. However, the prognosis for advanced cases is poor.

Cervical carcinoma is unlikely in this patient, as it typically presents with abnormal vaginal bleeding, discomfort, and discharge, which are not reported.

Cirrhosis of the liver is a possibility, but the patient does not display common signs and symptoms, such as coagulopathy, hepatic encephalopathy, or variceal bleeding.

Wilson disease is a rare inherited disorder of copper metabolism that can cause hepatic dysfunction, but this patient does not display the characteristic hyperpigmentation, hepatomegaly, or diabetes mellitus.

Haemochromatosis is also unlikely, as the patient does not display the clinical features of the disease, such as hyperpigmentation, hepatomegaly, or diabetes mellitus, and there is no evidence of iron overload.

In the UK, it is recommended that all women who are HIV-positive should not breastfeed their babies. This advice remains the same even if the mother’s viral load is undetectable. The decision should not be left to the HIV consultant as the national guidelines are clear on this matter. Although breastfeeding may reduce the risk of transmission if the maternal viral load is less than 50 copies/ml, there is still a risk involved. Therefore, the advice remains not to breastfeed. Continuing with antiretroviral therapy is expected regardless of the decision not to breastfeed as it significantly reduces the risk of vertical transmission during pregnancy. Babies born to HIV-positive mothers are given antiretroviral therapy, either zidovudine alone if the maternal viral load is less than 50 copies/ml or triple-therapy if it is higher. However, this does not change the advice to avoid breastfeeding.

HIV and Pregnancy: Guidelines for Minimizing Vertical Transmission

With the increasing prevalence of HIV infection among heterosexual individuals, there has been a rise in the number of HIV-positive women giving birth in the UK. In fact, in London alone, the incidence may be as high as 0.4% of pregnant women. The primary goal of treating HIV-positive women during pregnancy is to minimize harm to both the mother and fetus, and to reduce the chance of vertical transmission.

To achieve this goal, various factors must be considered. Firstly, all pregnant women should be offered HIV screening, according to NICE guidelines. Additionally, antiretroviral therapy should be offered to all pregnant women, regardless of whether they were taking it previously. This therapy has been shown to significantly reduce vertical transmission rates, which can range from 25-30% to just 2%.

The mode of delivery is also an important consideration. Vaginal delivery is recommended if the viral load is less than 50 copies/ml at 36 weeks. If the viral load is higher, a caesarean section is recommended, and a zidovudine infusion should be started four hours before the procedure. Neonatal antiretroviral therapy is also typically administered to the newborn, with zidovudine being the preferred medication if the maternal viral load is less than 50 copies/ml. If the viral load is higher, triple ART should be used, and therapy should be continued for 4-6 weeks.

Finally, infant feeding is an important consideration. In the UK, all women should be advised not to breastfeed, as this can increase the risk of vertical transmission. By following these guidelines, healthcare providers can help to minimize the risk of vertical transmission and ensure the best possible outcomes for both mother and child.

Understanding Endometriosis

Endometriosis is a common condition where endometrial tissue grows outside of the uterus. It affects around 10% of women of reproductive age and can cause chronic pelvic pain, painful periods, painful intercourse, and subfertility. Other symptoms may include urinary problems and painful bowel movements. Diagnosis is typically made through laparoscopy, and treatment options depend on the severity of symptoms.

First-line treatments for symptomatic relief include NSAIDs and/or paracetamol. If these do not help, hormonal treatments such as the combined oral contraceptive pill or progestogens may be tried. If symptoms persist or fertility is a priority, referral to secondary care may be necessary. Secondary treatments may include GnRH analogues or surgery. For women trying to conceive, laparoscopic excision or ablation of endometriosis plus adhesiolysis is recommended, as well as ovarian cystectomy for endometriomas.

It is important to note that there is poor correlation between laparoscopic findings and severity of symptoms, and that there is little role for investigation in primary care. If symptoms are significant, referral for a definitive diagnosis is recommended.

The recommended treatment for bacterial vaginosis in this patient is metronidazole, but high doses of this medication are not safe for breastfeeding. Fluconazole is used to treat thrush, while azithromycin is used for Chlamydia. Clarithromycin is prescribed for pneumonia, strep throat, and H. pylori infections.

Bacterial vaginosis (BV) is a condition where there is an overgrowth of anaerobic organisms, particularly Gardnerella vaginalis, in the vagina. This leads to a decrease in the amount of lactobacilli, which produce lactic acid, resulting in an increase in vaginal pH. BV is not a sexually transmitted infection, but it is commonly seen in sexually active women. Symptoms include a fishy-smelling vaginal discharge, although some women may not experience any symptoms at all. Diagnosis is made using Amsel’s criteria, which includes the presence of thin, white discharge, clue cells on microscopy, a vaginal pH greater than 4.5, and a positive whiff test. Treatment involves oral metronidazole for 5-7 days, with a cure rate of 70-80%. However, relapse rates are high, with over 50% of women experiencing a recurrence within 3 months. Topical metronidazole or clindamycin may be used as alternatives.

Bacterial vaginosis during pregnancy can increase the risk of preterm labor, low birth weight, chorioamnionitis, and late miscarriage. It was previously recommended to avoid oral metronidazole in the first trimester and use topical clindamycin instead. However, recent guidelines suggest that oral metronidazole can be used throughout pregnancy. The British National Formulary (BNF) still advises against using high-dose metronidazole regimes. Clue cells, which are vaginal epithelial cells covered with bacteria, can be seen on microscopy in women with BV.

Oral labetalol is the recommended initial treatment for this woman with moderate gestational hypertension, as per the current guidelines.

Hypertension during pregnancy is a common occurrence that requires careful management. In normal pregnancies, blood pressure tends to decrease in the first trimester and then gradually increase to pre-pregnancy levels by term. However, in cases of hypertension during pregnancy, the systolic blood pressure is usually above 140 mmHg or the diastolic blood pressure is above 90 mmHg. Additionally, an increase of more than 30 mmHg systolic or 15 mmHg diastolic from the initial readings may also indicate hypertension.

There are three categories of hypertension during pregnancy: pre-existing hypertension, pregnancy-induced hypertension (PIH), and pre-eclampsia. Pre-existing hypertension refers to a history of hypertension before pregnancy or elevated blood pressure before 20 weeks gestation. PIH occurs in the second half of pregnancy and resolves after birth. Pre-eclampsia is characterized by hypertension and proteinuria, and may also involve edema.

The management of hypertension during pregnancy involves the use of antihypertensive medications such as labetalol, nifedipine, and hydralazine. In cases of pre-existing hypertension, ACE inhibitors and angiotensin II receptor blockers should be stopped immediately and alternative medications should be prescribed. Women who are at high risk of developing pre-eclampsia should take aspirin from 12 weeks until the birth of the baby. It is important to carefully monitor blood pressure and proteinuria levels during pregnancy to ensure the health of both the mother and the baby.

Levonorgestrel should be taken within 72 hours of unprotected sexual intercourse (UPSI). Administration of a single dose of levonorgestrel after this time is not licensed but may be considered.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, while ulipristal primarily inhibits ovulation. Levonorgestrel should be taken as soon as possible after unprotected sexual intercourse, within 72 hours, and is 84% effective when used within this time frame. The dose should be doubled for those with a BMI over 26 or weight over 70kg. Ulipristal should be taken within 120 hours of intercourse and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which can be inserted within 5 days of unprotected intercourse or up to 5 days after the likely ovulation date. It may inhibit fertilization or implantation and is 99% effective regardless of where it is used in the cycle. Prophylactic antibiotics may be given if the patient is at high risk of sexually transmitted infection.

Women who have had a previous baby affected by early- or late-onset GBS disease should be offered maternal intravenous antibiotic prophylaxis. The recommended option is to prescribe intrapartum intravenous benzylpenicillin or ampicillin to the mother. This is according to the Royal College of Obstetricians and Gynaecologists guidelines published in 2017. Administering intravenous benzylpenicillin to the child at birth is not appropriate unless they show signs of neonatal sepsis. Prescribing intrapartum intravenous ceftazidime is also not recommended. Monitoring the newborn for signs of sepsis for the next 72 hours is not sufficient in this case. The best approach is to administer antibiotics to the mother to prevent the development of neonatal sepsis.

Group B Streptococcus (GBS) is a common cause of severe infection in newborns. It is estimated that 20-40% of mothers carry GBS in their bowel flora, which can be passed on to their infants during labor and lead to serious infections. Prematurity, prolonged rupture of membranes, previous sibling GBS infection, and maternal pyrexia are all risk factors for GBS infection. The Royal College of Obstetricians and Gynaecologists (RCOG) has published guidelines on GBS management, which include not offering universal screening for GBS to all women and not offering screening based on maternal request. Women who have had GBS detected in a previous pregnancy should be offered intrapartum antibiotic prophylaxis (IAP) or testing in late pregnancy and antibiotics if still positive. IAP should also be offered to women with a previous baby with GBS disease, women in preterm labor, and women with a fever during labor. Benzylpenicillin is the preferred antibiotic for GBS prophylaxis.

If the 1st repeat smear at 12 months for cervical cancer screening is now negative for hrHPV, the patient should return to routine recall, which is repeating the cervical smear in 5 years. Cytological examination of the smear is not necessary as the NHS now follows an HPV first system. Referral for colposcopy is also not indicated unless there is evidence of dyskaryosis or inadequate smears. Repeating the cervical smear in 3 years is not appropriate for a 50-year-old patient, and repeating the smear after 12 months is only necessary if the most recent smear is positive for hrHPV with no cytological abnormalities.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

If the woman does not approve of hormonal treatments, alternatives such as tranexamic acid or NSAIDs can be utilized according to NICE CG44.

Managing Heavy Menstrual Bleeding

Heavy menstrual bleeding, also known as menorrhagia, is a condition where a woman experiences excessive blood loss during her menstrual cycle. While it was previously defined as total blood loss of over 80 ml per cycle, the management of menorrhagia now depends on the woman’s perception of what is excessive. In the past, hysterectomy was a common treatment for heavy periods, but the approach has changed significantly since the 1990s.

To manage menorrhagia, a full blood count should be performed in all women. If symptoms suggest a structural or histological abnormality, a routine transvaginal ultrasound scan should be arranged. For women who do not require contraception, mefenamic acid or tranexamic acid can be used. If there is no improvement, other drugs can be tried while awaiting referral.

For women who require contraception, options include the intrauterine system (Mirena), combined oral contraceptive pill, and long-acting progestogens. Norethisterone can also be used as a short-term option to rapidly stop heavy menstrual bleeding. The flowchart below shows the management of menorrhagia.

[Insert flowchart here]

The primary way in which Nexplanon works is by preventing ovulation.

Implanon and Nexplanon are subdermal contraceptive implants that slowly release the progestogen hormone etonogestrel to prevent ovulation and thicken cervical mucus. Nexplanon is the newer version and has a redesigned applicator to prevent deep insertions and is radiopaque for easier location. It is highly effective with a failure rate of 0.07/100 women-years and lasts for 3 years. It does not contain estrogen, making it suitable for women with a past history of thromboembolism or migraine. It can be inserted immediately after a termination of pregnancy. However, a trained professional is needed for insertion and removal, and additional contraceptive methods are required for the first 7 days if not inserted on days 1 to 5 of a woman’s menstrual cycle.

The main disadvantage of these implants is irregular and heavy bleeding, which can be managed with a co-prescription of the combined oral contraceptive pill. Other adverse effects include headache, nausea, and breast pain. Enzyme-inducing drugs such as certain antiepileptic and rifampicin may reduce the efficacy of Nexplanon, and women should switch to a method unaffected by enzyme-inducing drugs or use additional contraception until 28 days after stopping the treatment.

There are also contraindications for using these implants, such as ischaemic heart disease/stroke, unexplained, suspicious vaginal bleeding, past breast cancer, severe liver cirrhosis, and liver cancer. Current breast cancer is a UKMEC 4 condition, which represents an unacceptable risk if the contraceptive method is used. Overall, these implants are a highly effective and long-acting form of contraception, but they require careful consideration of the potential risks and contraindications.

Medical treatment can be attempted for uterine fibroids that are smaller than 3 cm and do not distort the uterine cavity. This may include options such as an intrauterine system, tranexamic acid, or COCP. The NICE Clinical Knowledge Summaries suggest starting with an intrauterine system, which can also serve as a form of contraception.

Understanding Uterine Fibroids

Uterine fibroids are non-cancerous growths that develop in the uterus. They are more common in black women and are thought to occur in around 20% of white women in their later reproductive years. Fibroids are usually asymptomatic, but they can cause menorrhagia, which can lead to iron-deficiency anaemia. Other symptoms include lower abdominal pain, bloating, and urinary symptoms. Fibroids may also cause subfertility.

Diagnosis is usually made through transvaginal ultrasound. Asymptomatic fibroids do not require treatment, but periodic monitoring is recommended. Menorrhagia secondary to fibroids can be managed with various treatments, including the levonorgestrel intrauterine system, NSAIDs, tranexamic acid, and hormonal therapies.

Medical treatment to shrink or remove fibroids may include GnRH agonists or ulipristal acetate, although the latter is not currently recommended due to concerns about liver toxicity. Surgical options include myomectomy, hysteroscopic endometrial ablation, hysterectomy, and uterine artery embolization.

Fibroids generally regress after menopause, but complications such as subfertility and iron-deficiency anaemia can occur. Red degeneration, which is haemorrhage into the tumour, is a common complication during pregnancy.

Levonorgestrel (Levonelle) can be followed immediately by hormonal contraception for emergency contraception.

Patients can resume their regular pill regimen right after taking levonorgestrel for emergency contraception. Levonorgestrel is an approved method of emergency contraception that can be used within 72 hours of unprotected sexual intercourse. It is the preferred oral emergency contraceptive for patients with asthma, as ulipristal is not recommended for those with severe asthma. Unlike ulipristal, which requires a waiting period of 5 days, patients can start hormonal contraception immediately after taking levonorgestrel. However, patients should use condoms for 7 days after restarting their combined oral contraceptive pill (COCP). It is important to note that the other options provided are incorrect. The progesterone-only pill requires condom use for 48 hours, unless initiated within the first 5 days of the menstrual cycle. Ulipristal acetate requires a waiting period of 5 days before restarting hormonal contraception. The COCP requires condom use for 7 days after restarting.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, while ulipristal primarily inhibits ovulation. Levonorgestrel should be taken as soon as possible after unprotected sexual intercourse, within 72 hours, and is 84% effective when used within this time frame. The dose should be doubled for those with a BMI over 26 or weight over 70kg. Ulipristal should be taken within 120 hours of intercourse and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which can be inserted within 5 days of unprotected intercourse or up to 5 days after the likely ovulation date. It may inhibit fertilization or implantation and is 99% effective regardless of where it is used in the cycle. Prophylactic antibiotics may be given if the patient is at high risk of sexually transmitted infection.

Management of Syphilis

Syphilis can be effectively managed with intramuscular benzathine penicillin as the first-line treatment. In cases where penicillin cannot be used, doxycycline may be used as an alternative. After treatment, nontreponemal titres such as rapid plasma reagin (RPR) or Venereal Disease Research Laboratory (VDRL) should be monitored to assess the response. A fourfold decline in titres is often considered an adequate response to treatment.

It is important to note that the Jarisch-Herxheimer reaction may occur following treatment. This reaction is characterized by fever, rash, and tachycardia after the first dose of antibiotic. Unlike anaphylaxis, there is no wheezing or hypotension. The reaction is thought to be due to the release of endotoxins following bacterial death and typically occurs within a few hours of treatment. However, no treatment is needed other than antipyretics if required.

In summary, the management of syphilis involves the use of intramuscular benzathine penicillin or doxycycline as an alternative. Nontreponemal titres should be monitored after treatment, and the Jarisch-Herxheimer reaction may occur but does not require treatment unless symptomatic.

Pregnant women who have mild or moderate gestational hypertension, are beyond 37 weeks of pregnancy, and exhibit pre-eclampsia symptoms, should be advised to deliver their baby within 24 to 48 hours as per the existing recommendations.

Hypertension during pregnancy is a common occurrence that requires careful management. In normal pregnancies, blood pressure tends to decrease in the first trimester and then gradually increase to pre-pregnancy levels by term. However, in cases of hypertension during pregnancy, the systolic blood pressure is usually above 140 mmHg or the diastolic blood pressure is above 90 mmHg. Additionally, an increase of more than 30 mmHg systolic or 15 mmHg diastolic from the initial readings may also indicate hypertension.

There are three categories of hypertension during pregnancy: pre-existing hypertension, pregnancy-induced hypertension (PIH), and pre-eclampsia. Pre-existing hypertension refers to a history of hypertension before pregnancy or elevated blood pressure before 20 weeks gestation. PIH occurs in the second half of pregnancy and resolves after birth. Pre-eclampsia is characterized by hypertension and proteinuria, and may also involve edema.

The management of hypertension during pregnancy involves the use of antihypertensive medications such as labetalol, nifedipine, and hydralazine. In cases of pre-existing hypertension, ACE inhibitors and angiotensin II receptor blockers should be stopped immediately and alternative medications should be prescribed. Women who are at high risk of developing pre-eclampsia should take aspirin from 12 weeks until the birth of the baby. It is important to carefully monitor blood pressure and proteinuria levels during pregnancy to ensure the health of both the mother and the baby.

Primary dysmenorrhoea is best treated with NSAIDs like mefenamic acid, which are the first line of treatment according to NICE guidelines. Paracetamol can be used if NSAIDs are not suitable, and a combination of both can be tried if NSAIDs alone are not effective. Hormonal options like the combined oral contraceptive pill can also be considered, but contraindications must be ruled out. The intrauterine device or copper coil is not recommended for this patient due to the risk of heavier bleeding. Instead, the intrauterine system or Mirena coil can be offered as an alternative option. While the IUS is the first-line treatment for menorrhagia, NSAIDs are the initial choice for primary dysmenorrhoea. It is important to consider the patient’s plans for conception when deciding on treatment options.

Dysmenorrhoea is a condition where women experience excessive pain during their menstrual period. There are two types of dysmenorrhoea: primary and secondary. Primary dysmenorrhoea affects up to 50% of menstruating women and is not caused by any underlying pelvic pathology. It usually appears within 1-2 years of the menarche and is thought to be partially caused by excessive endometrial prostaglandin production. Symptoms include suprapubic cramping pains that may radiate to the back or down the thigh, and pain typically starts just before or within a few hours of the period starting. NSAIDs such as mefenamic acid and ibuprofen are effective in up to 80% of women, and combined oral contraceptive pills are used second line for management.

Secondary dysmenorrhoea, on the other hand, typically develops many years after the menarche and is caused by an underlying pathology. The pain usually starts 3-4 days before the onset of the period. Causes of secondary dysmenorrhoea include endometriosis, adenomyosis, pelvic inflammatory disease, intrauterine devices, and fibroids. Clinical Knowledge Summaries recommend referring all patients with secondary dysmenorrhoea to gynaecology for investigation. It is important to note that the intrauterine system (Mirena) may help dysmenorrhoea, but this only applies to normal copper coils.

When simple analgesia fails to alleviate endometriosis-related pain, the next step in treatment is to try either progestogens or the combined oral contraceptive pill. These hormonal treatments are generally effective in managing the symptoms of endometriosis. While clomifene may be used to induce ovulation in certain conditions, it is not the recommended next step in pain management for endometriosis. Elagolix, a new gonadotropin-releasing hormone antagonist, is licensed in the USA for endometriosis-related pain but is not widely used in the UK. Laparoscopic excision is a more invasive option and is typically reserved for later stages of treatment. Therefore, hormonal options are the next most appropriate step after simple analgesia for managing endometriosis-related pain.

Understanding Endometriosis

Endometriosis is a common condition where endometrial tissue grows outside of the uterus. It affects around 10% of women of reproductive age and can cause chronic pelvic pain, painful periods, painful intercourse, and subfertility. Other symptoms may include urinary problems and painful bowel movements. Diagnosis is typically made through laparoscopy, and treatment options depend on the severity of symptoms.

First-line treatments for symptomatic relief include NSAIDs and/or paracetamol. If these do not help, hormonal treatments such as the combined oral contraceptive pill or progestogens may be tried. If symptoms persist or fertility is a priority, referral to secondary care may be necessary. Secondary treatments may include GnRH analogues or surgery. For women trying to conceive, laparoscopic excision or ablation of endometriosis plus adhesiolysis is recommended, as well as ovarian cystectomy for endometriomas.

It is important to note that there is poor correlation between laparoscopic findings and severity of symptoms, and that there is little role for investigation in primary care. If symptoms are significant, referral for a definitive diagnosis is recommended.

Benefits and Risks of Hormone Replacement Therapy (HRT)

Hormone Replacement Therapy (HRT) is a treatment used to alleviate the symptoms of menopause, such as hot flushes, sweating, and palpitations. It has been proven effective in placebo-controlled randomized studies. HRT can also improve vaginal dryness, superficial dyspareunia, and urinary frequency and urgency. Long-term therapy is required to achieve these benefits, and symptoms may recur after stopping HRT.

HRT is commonly prescribed to prevent osteoporosis, particularly if started within the first five years after menopause onset. Women with decreased bone mineral density and those with a history of osteoporotic fractures also benefit from HRT. However, protection may be lost after stopping the hormones. HRT can reduce the incidence of hip fractures by about one case per 1000 women aged <70 years and by about 8 cases per 1000 women aged 70–79 years. The Women’s Health Initiative (WHI) study revealed an increased annual risk of heart attacks in women who took combined HRT compared to those who took estrogen only. HRT may also prevent and treat dementia and related disorders by enhancing cholinergic neurotransmission and preventing oxidative cell damage, neuronal atrophy, and glucocorticoid-induced neuronal damage. However, studies have failed to provide a consensus on this aspect due to issues of selection bias and extreme heterogeneity in study participants, treatments, cognitive function tests applied, and doses of HRT. In conclusion, HRT can provide relief for menopausal symptoms, improve vaginal health, prevent osteoporosis, and reduce the risk of heart attacks. However, it may increase the risk of dementia, particularly in women aged 65 years who take combination HRT and have relatively low cognitive function at the start of treatment. Therefore, the benefits and risks of HRT should be carefully considered before starting treatment.

Women who have experienced heavy menstrual bleeding since their first period and have indications of a coagulation disorder in their personal or family medical history should undergo testing for such disorders, including von Willebrand’s disease. This recommendation is made by NICE CG44.

Understanding Menorrhagia: Causes and Definition

Menorrhagia is a condition characterized by heavy menstrual bleeding. While it was previously defined as total blood loss exceeding 80 ml per menstrual cycle, the assessment and management of the condition now focuses on the woman’s perception of excessive bleeding and its impact on her quality of life. Dysfunctional uterine bleeding, which occurs in the absence of underlying pathology, is the most common cause of menorrhagia, accounting for about half of all cases. Anovulatory cycles, uterine fibroids, hypothyroidism, pelvic inflammatory disease, and bleeding disorders such as von Willebrand disease are other potential causes of menorrhagia. It is important to note that the use of intrauterine devices, specifically copper coils, may also contribute to heavy menstrual bleeding. However, the intrauterine system (Mirena) is a treatment option for menorrhagia.

If a person experiences more than 2 migraine attacks a month, they should be offered migraine prophylaxis. Propranolol and topiramate are both options for this, but propranolol is preferred for women of child-bearing age due to the risk of cleft lip/cleft palate in infants if topiramate is used during the first trimester of pregnancy. The combined oral contraceptive pill is not typically prescribed for migraines, and if a patient using it becomes pregnant, it will not harm the fetus. Triptan medications like sumatriptan and zolmitriptan are used for acute migraine treatment and should be taken as soon as a migraine starts. They may also be used for menstrual migraine prophylaxis, but should be avoided during pregnancy due to limited safety data.

Managing Migraines: Guidelines and Treatment Options

Migraines can be debilitating and affect a significant portion of the population. To manage migraines, it is important to understand the different treatment options available. According to the National Institute for Health and Care Excellence (NICE) guidelines, acute treatment for migraines involves a combination of an oral triptan and an NSAID or paracetamol. For young people aged 12-17 years, a nasal triptan may be preferred. If these measures are not effective, non-oral preparations of metoclopramide or prochlorperazine may be considered, along with a non-oral NSAID or triptan.

Prophylaxis should be given if patients are experiencing two or more attacks per month. NICE recommends topiramate or propranolol, depending on the patient’s preference, comorbidities, and risk of adverse events. Propranolol is preferred in women of childbearing age as topiramate may be teratogenic and reduce the effectiveness of hormonal contraceptives. Acupuncture and riboflavin may also be effective in reducing migraine frequency and intensity for some people. For women with predictable menstrual migraines, frovatriptan or zolmitriptan may be recommended as a type of mini-prophylaxis.

Specialists may consider other treatment options, such as candesartan or monoclonal antibodies directed against the calcitonin gene-related peptide (CGRP) receptor, like erenumab. However, pizotifen is no longer recommended due to common adverse effects like weight gain and drowsiness. It is important to exercise caution with young patients as acute dystonic reactions may develop. By following these guidelines and considering various treatment options, migraines can be effectively managed.

Ulipristal, also known as EllaOne, is a form of emergency hormonal contraception that can be taken within 120 hours after engaging in unprotected sexual intercourse.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, while ulipristal primarily inhibits ovulation. Levonorgestrel should be taken as soon as possible after unprotected sexual intercourse, within 72 hours, and is 84% effective when used within this time frame. The dose should be doubled for those with a BMI over 26 or weight over 70kg. Ulipristal should be taken within 120 hours of intercourse and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which can be inserted within 5 days of unprotected intercourse or up to 5 days after the likely ovulation date. It may inhibit fertilization or implantation and is 99% effective regardless of where it is used in the cycle. Prophylactic antibiotics may be given if the patient is at high risk of sexually transmitted infection.

The appropriate medical treatments for postpartum haemorrhage caused by uterine atony are oxytocin, ergometrine, carboprost, and misoprostol. In this scenario, the patient has experienced a blood loss of over 500 ml after delivery, indicating PPH as the likely cause, with uterine atony being the most probable reason. The first steps in managing PPH involve an ABCDE approach, including IV access, warm crystalloid administration, uterine fundus palpation, and catheterisation to prevent bladder distention. If these measures fail, medical therapy is initiated, starting with IV oxytocin. IM carboprost is not the correct choice as it requires senior approval and can worsen bronchoconstriction in patients with asthma. IV carboprost is also not recommended as it can cause bronchospasm, hypertension, and fever, and requires senior approval. IV tocolytics are not appropriate as they suppress uterine contractions, which would exacerbate the problem in this case. Therefore, agents that stimulate uterine contraction are given to manage PPH caused by uterine atony.

Understanding Postpartum Haemorrhage

Postpartum haemorrhage (PPH) is a condition where a woman experiences blood loss of more than 500 ml after giving birth vaginally. It can be classified as primary or secondary. Primary PPH occurs within 24 hours after delivery and is caused by the 4 Ts: tone, trauma, tissue, and thrombin. The most common cause is uterine atony. Risk factors for primary PPH include previous PPH, prolonged labour, pre-eclampsia, increased maternal age, emergency Caesarean section, and placenta praevia.

In managing PPH, it is important to involve senior staff immediately and follow the ABC approach. This includes two peripheral cannulae, lying the woman flat, blood tests, and commencing a warmed crystalloid infusion. Mechanical interventions such as rubbing up the fundus and catheterisation are also done. Medical interventions include IV oxytocin, ergometrine, carboprost, and misoprostol. Surgical options such as intrauterine balloon tamponade, B-Lynch suture, ligation of uterine arteries, and hysterectomy may be considered if medical options fail to control the bleeding.

Secondary PPH occurs between 24 hours to 6 weeks after delivery and is typically due to retained placental tissue or endometritis. It is important to understand the causes and risk factors of PPH to prevent and manage this life-threatening emergency effectively.

If enzyme-inducing drugs are taken at the same time as the combined oral contraceptive pill, its effectiveness is decreased. Out of the given choices, only St John’s wort is an enzyme inducer, while the rest are enzyme inhibitors.

Counselling for Women Considering the Combined Oral Contraceptive Pill

Women who are considering taking the combined oral contraceptive pill (COC) should receive counselling on the potential harms and benefits of the pill. The COC is highly effective if taken correctly, with a success rate of over 99%. However, there is a small risk of blood clots, heart attacks, and strokes, as well as an increased risk of breast and cervical cancer.

In addition to discussing the potential risks and benefits, women should also receive advice on how to take the pill. If the COC is started within the first 5 days of the menstrual cycle, there is no need for additional contraception. However, if it is started at any other point in the cycle, alternative contraception should be used for the first 7 days. Women should take the pill at the same time every day and should be aware that intercourse during the pill-free period is only safe if the next pack is started on time.

There have been recent changes to the guidelines for taking the COC. While it was previously recommended to take the pill for 21 days and then stop for 7 days to mimic menstruation, it is now recommended to discuss tailored regimes with women. This is because there is no medical benefit to having a withdrawal bleed, and options include never having a pill-free interval or taking three 21-day packs back-to-back before having a 4 or 7 day break.

Women should also be informed of situations where the efficacy of the pill may be reduced, such as vomiting within 2 hours of taking the pill, medication that induces diarrhoea or vomiting, or taking liver enzyme-inducing drugs. It is also important to discuss sexually transmitted infections and precautions that should be taken with enzyme-inducing antibiotics such as rifampicin.

Overall, counselling for women considering the COC should cover a range of topics to ensure that they are fully informed and able to make an informed decision about their contraceptive options.

The procedure being performed is called an episiotomy, which can be done using various techniques. In this case, the medio-lateral approach is being used, which involves making a cut at either the 7 o’clock or 5 o’clock positions. The main reasons for performing this procedure are twofold. Firstly, it helps to prevent the vagina from tearing during childbirth, particularly in cases where the baby’s head is too large for the mother’s pelvis. By making a controlled incision, the risk of the tear extending towards the anus and surrounding muscles is reduced, which could lead to long-term problems such as fecal incontinence. Secondly, the episiotomy creates more space for the baby to pass through, making delivery easier and safer for both the mother and child.

Understanding Episiotomy

Episiotomy is a surgical procedure that involves making an incision in the posterior wall of the vagina and perineum during the second stage of labor. This procedure is done to make it easier for the baby to pass through the birth canal. The incision is made in the area between the vagina and anus, and it can be either midline or mediolateral.

Episiotomy is usually performed when the baby is in distress, and there is a need to speed up the delivery process. It can also be done to prevent tearing of the perineum, which can be more difficult to repair than an episiotomy. However, the procedure is not without risks, and it can lead to complications such as pain, infection, and bleeding.

In recent years, there has been a decline in the use of episiotomy, as studies have shown that it does not necessarily reduce the risk of tearing or improve healing time. Many healthcare providers now only perform episiotomy when it is medically necessary. It is important for expectant mothers to discuss the use of episiotomy with their healthcare provider and understand the risks and benefits before making a decision.

If the COC is initiated on the first day of the menstrual cycle, it becomes effective immediately. However, if it is started on any other day, additional contraception such as condoms should be used for the first 7 days. The injection, implant, IUS, and POP require 7 days to become effective, while the IUD is effective immediately upon insertion.

Counselling for Women Considering the Combined Oral Contraceptive Pill

Women who are considering taking the combined oral contraceptive pill (COC) should receive counselling on the potential harms and benefits of the pill. The COC is highly effective if taken correctly, with a success rate of over 99%. However, there is a small risk of blood clots, heart attacks, and strokes, as well as an increased risk of breast and cervical cancer.

In addition to discussing the potential risks and benefits, women should also receive advice on how to take the pill. If the COC is started within the first 5 days of the menstrual cycle, there is no need for additional contraception. However, if it is started at any other point in the cycle, alternative contraception should be used for the first 7 days. Women should take the pill at the same time every day and should be aware that intercourse during the pill-free period is only safe if the next pack is started on time.

There have been recent changes to the guidelines for taking the COC. While it was previously recommended to take the pill for 21 days and then stop for 7 days to mimic menstruation, it is now recommended to discuss tailored regimes with women. This is because there is no medical benefit to having a withdrawal bleed, and options include never having a pill-free interval or taking three 21-day packs back-to-back before having a 4 or 7 day break.

Women should also be informed of situations where the efficacy of the pill may be reduced, such as vomiting within 2 hours of taking the pill, medication that induces diarrhoea or vomiting, or taking liver enzyme-inducing drugs. It is also important to discuss sexually transmitted infections and precautions that should be taken with enzyme-inducing antibiotics such as rifampicin.

Overall, counselling for women considering the COC should cover a range of topics to ensure that they are fully informed and able to make an informed decision about their contraceptive options.

According to FSRH guidelines, it is acceptable to begin hormonal contraception immediately after taking levonorgestrel (Levonelle) for emergency contraception. It is important to wait 5 days after taking ulipristal acetate (Ella-OneTM) before starting ongoing hormonal contraception. Waiting until the start of the next menstrual period is not necessary for quick-starting hormonal contraception, which can be done if the patient prefers it or if there is ongoing risk of pregnancy. While a negative pregnancy test at 21 days post-UPSI can reasonably exclude pregnancy, it is still recommended to take a pregnancy test 21 days after the episode of UPSI in case emergency contraception has failed.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, while ulipristal primarily inhibits ovulation. Levonorgestrel should be taken as soon as possible after unprotected sexual intercourse, within 72 hours, and is 84% effective when used within this time frame. The dose should be doubled for those with a BMI over 26 or weight over 70kg. Ulipristal should be taken within 120 hours of intercourse and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which can be inserted within 5 days of unprotected intercourse or up to 5 days after the likely ovulation date. It may inhibit fertilization or implantation and is 99% effective regardless of where it is used in the cycle. Prophylactic antibiotics may be given if the patient is at high risk of sexually transmitted infection.

When it comes to providing contraception to young people, there are legal and ethical considerations to take into account. In the UK, the age of consent for sexual activity is 16 years, but practitioners may still offer advice and contraception to young people they deem competent. The Fraser Guidelines are often used to assess a young person’s competence. Children under the age of 13 are considered unable to consent to sexual intercourse, and consultations regarding this age group should trigger child protection measures automatically.

It’s important to advise young people to have STI tests 2 and 12 weeks after an incident of unprotected sexual intercourse. Long-acting reversible contraceptive methods (LARCs) are often the best choice for young people, as they may be less reliable in remembering to take medication. However, there are concerns about the effect of progesterone-only injections (Depo-provera) on bone mineral density, and the UKMEC category of the IUS and IUD is 2 for women under the age of 20 years, meaning they may not be the best choice. The progesterone-only implant (Nexplanon) is therefore the LARC of choice for young people.

For this patient, who has a low risk of having a baby with neural tube defects and is not at high risk of vitamin D deficiency, the standard care is recommended. This includes taking a daily supplement of 10 micrograms of vitamin D. There is no need for her to take folic acid 5mg or higher doses of vitamin D, as they exceed the recommended amount.

Antenatal care guidelines were issued by NICE in March 2008, which included specific points for the care of healthy pregnant women. Nausea and vomiting can be treated with natural remedies such as ginger and acupuncture on the ‘p6’ point, as recommended by NICE. Antihistamines, with promethazine as the first-line option according to the BNF, can also be used. Adequate vitamin D intake is crucial for the health of both the mother and baby, and women should be informed about this at their booking appointment. The Chief Medical Officer advises all pregnant and breastfeeding women to take a daily supplement containing 10 micrograms of vitamin D, with particular care taken for those at risk. In 2016, new guidelines were proposed by the Chief Medical Officer regarding alcohol consumption during pregnancy. The government now advises pregnant women not to drink any alcohol to minimize the risk of harm to the baby.

Liver Disorders in Pregnancy: Differential Diagnosis

During pregnancy, various liver disorders can occur, each with its own set of symptoms and potential complications. Here are some of the most common liver disorders that can occur during pregnancy and their distinguishing features:

1. Hyperemesis gravidarum: This is the most severe form of nausea and vomiting in pregnancy, which can lead to weight loss, dehydration, and electrolyte imbalances. It is characterised by persistent nausea and vomiting, and may require hospitalisation.

2. Acute fatty liver of pregnancy: This is a rare but serious complication that can occur in the third trimester. It is characterised by microvesicular steatosis in the liver, which can lead to liver insufficiency. Symptoms include malaise, nausea and vomiting, right upper quadrant and epigastric pain, and acute renal failure.

3. Intrahepatic cholestasis of pregnancy: This is the most common pregnancy-related liver disorder, characterised by generalised itching, particularly in the palms and soles, and jaundice. It is caused by hormonal changes and can lead to fetal complications if not treated promptly.

4. Pre-eclampsia: This is a disorder of widespread vascular malfunction that occurs after 20 weeks of gestation. It is characterised by hypertension and proteinuria, with or without oedema.

5. Biliary tract disease: This is a broad spectrum of disorders ranging from asymptomatic gallstones to cholecystitis and choledocholithiasis. Symptoms include biliary colic, inflammation of the gall bladder wall, and obstruction of the common bile duct.

It is important to differentiate between these liver disorders in pregnancy, as each requires a different approach to management and treatment. Consultation with a healthcare provider is recommended for proper diagnosis and management.

For the treatment of menorrhagia, the first-line option would be the intrauterine system. Specifically, the Mirena, which contains levonorgestrel, is highly effective in treating menorrhagia and also serves as a long-acting reversible contraceptive. While the combined oral contraceptive pill, tranexamic acid, and mefenamic acid may provide relief from symptoms, they are not the preferred initial treatment. On the other hand, the intrauterine device would not be suitable for addressing this patient’s menorrhagia.

Managing Heavy Menstrual Bleeding

Heavy menstrual bleeding, also known as menorrhagia, is a condition where a woman experiences excessive blood loss during her menstrual cycle. While it was previously defined as total blood loss of over 80 ml per cycle, the management of menorrhagia now depends on the woman’s perception of what is excessive. In the past, hysterectomy was a common treatment for heavy periods, but the approach has changed significantly since the 1990s.

To manage menorrhagia, a full blood count should be performed in all women. If symptoms suggest a structural or histological abnormality, a routine transvaginal ultrasound scan should be arranged. For women who do not require contraception, mefenamic acid or tranexamic acid can be used. If there is no improvement, other drugs can be tried while awaiting referral.

For women who require contraception, options include the intrauterine system (Mirena), combined oral contraceptive pill, and long-acting progestogens. Norethisterone can also be used as a short-term option to rapidly stop heavy menstrual bleeding. The flowchart below shows the management of menorrhagia.

[Insert flowchart here]

Postpartum haemorrhage caused by uterine atony can be treated with various medical options such as oxytocin, ergometrine, carboprost and misoprostol.

Uterine atony is the primary cause of postpartum haemorrhage, which occurs when the uterus fails to contract fully after the delivery of the placenta, leading to difficulty in achieving haemostasis. This condition is often associated with overdistension, which can be caused by multiple gestation, macrosomia, polyhydramnios or other factors.

In addition to the standard approach for managing PPH, including an ABC approach for unstable patients, the following steps should be taken in sequence:

1. Bimanual uterine compression to stimulate contraction manually
2. Intravenous oxytocin and/or ergometrine
3. Intramuscular carboprost
4. Intramyometrial carboprost
5. Rectal misoprostol
6. Surgical intervention such as balloon tamponade

(RCOG Green-top Guideline No. 52)

Understanding Postpartum Haemorrhage

Postpartum haemorrhage (PPH) is a condition where a woman experiences blood loss of more than 500 ml after giving birth vaginally. It can be classified as primary or secondary. Primary PPH occurs within 24 hours after delivery and is caused by the 4 Ts: tone, trauma, tissue, and thrombin. The most common cause is uterine atony. Risk factors for primary PPH include previous PPH, prolonged labour, pre-eclampsia, increased maternal age, emergency Caesarean section, and placenta praevia.

In managing PPH, it is important to involve senior staff immediately and follow the ABC approach. This includes two peripheral cannulae, lying the woman flat, blood tests, and commencing a warmed crystalloid infusion. Mechanical interventions such as rubbing up the fundus and catheterisation are also done. Medical interventions include IV oxytocin, ergometrine, carboprost, and misoprostol. Surgical options such as intrauterine balloon tamponade, B-Lynch suture, ligation of uterine arteries, and hysterectomy may be considered if medical options fail to control the bleeding.

Secondary PPH occurs between 24 hours to 6 weeks after delivery and is typically due to retained placental tissue or endometritis. It is important to understand the causes and risk factors of PPH to prevent and manage this life-threatening emergency effectively.

Urinary incontinence is a common problem that affects more women than men and increases with age. There are different types of urinary incontinence, each with its own set of symptoms. Functional incontinence occurs when a person is unable to hold urine due to reasons other than lower urinary tract dysfunction, such as delirium or impaired mobility. Mixed incontinence is a combination of stress and urge incontinence, while overflow incontinence occurs when the bladder is overdistended and urine overflows despite the absence of detrusor contraction. Stress incontinence is characterized by urine loss during periods of increased intra-abdominal pressure, while urge incontinence is associated with a sudden and intense desire to void that cannot be prevented. Symptoms of urge incontinence include urinary frequency and nocturia. Treatment is directed at the underlying cause of the incontinence.

The earliest possible time for an anomaly scan is at 18 weeks, with the latest being at 20 weeks and 6 days. For a dating scan, the earliest possible time is at 8 weeks. As for a nuchal scan, it can be done at the earliest at 11 weeks.

NICE guidelines recommend 10 antenatal visits for first pregnancies and 7 for subsequent pregnancies if uncomplicated. The purpose of each visit is outlined, including booking visits, scans, screening for Down’s syndrome, routine care for blood pressure and urine, and discussions about labour and birth plans. Rhesus negative women are offered anti-D prophylaxis at 28 and 34 weeks. The guidelines also recommend discussing options for prolonged pregnancy at 41 weeks.

In the case of a pregnant woman who is not immune to rubella, it is recommended to offer the MMR vaccination after giving birth. Rubella can cause severe harm to the developing foetus, especially during the first 8-10 weeks of pregnancy. Although congenital rubella syndrome is now rare due to widespread MMR vaccination, there has been a resurgence of measles, mumps, and rubella outbreaks in developed countries due to the anti-vaccination movement. The woman should avoid contact with individuals who may have rubella and cannot receive the vaccine while pregnant. Referral to an obstetrician is not necessary at this time since the woman is asymptomatic and in good health. The MMR vaccine should not be administered at 20 weeks of pregnancy, and if the woman is not immune, it should be offered postnatally. If there is a suspicion of rubella based on the woman’s clinical presentation, the local Health Protection Team should be notified, but this is not necessary in this case since there is no suspicion.

Rubella and Pregnancy: Risks, Features, Diagnosis, and Management

Rubella, also known as German measles, is a viral infection caused by the togavirus. Thanks to the introduction of the MMR vaccine, it is now rare. However, if contracted during pregnancy, there is a risk of congenital rubella syndrome, which can cause serious harm to the fetus. It is important to note that the incubation period is 14-21 days, and individuals are infectious from 7 days before symptoms appear to 4 days after the onset of the rash.

The risk of damage to the fetus is highest in the first 8-10 weeks of pregnancy, with a risk as high as 90%. However, damage is rare after 16 weeks. Features of congenital rubella syndrome include sensorineural deafness, congenital cataracts, congenital heart disease (e.g. patent ductus arteriosus), growth retardation, hepatosplenomegaly, purpuric skin lesions, ‘salt and pepper’ chorioretinitis, microphthalmia, and cerebral palsy.

If a suspected case of rubella in pregnancy arises, it should be discussed immediately with the local Health Protection Unit (HPU) as type/timing of investigations may vary. IgM antibodies are raised in women recently exposed to the virus. It should be noted that it is very difficult to distinguish rubella from parvovirus B19 clinically. Therefore, it is important to also check parvovirus B19 serology as there is a 30% risk of transplacental infection, with a 5-10% risk of fetal loss.

If a woman is tested at any point and no immunity is demonstrated, they should be advised to keep away from people who might have rubella. Non-immune mothers should be offered the MMR vaccination in the post-natal period. However, MMR vaccines should not be administered to women known to be pregnant or attempting to become pregnant.

The patient is diagnosed with pre-eclampsia. According to the National Institute for Health and Care Excellence, initial treatment for severe hypertension in pregnancy (160/110mmHg or higher) should be labetalol. Delivery should not be considered before 34 weeks, unless the hypertension remains unresponsive to treatment or there are maternal or fetal indications as specified by the consultant plan. After completing a course of corticosteroids, delivery should be offered to women with pre-eclampsia at 34 weeks. In critical care situations, intravenous magnesium sulphate may be used for women who have previously experienced eclamptic fits due to severe hypertension or pre-eclampsia, but not solely to lower blood pressure. Frusemide should not be used to treat hypertension in pregnancy as it can reduce placental perfusion and cross the placental barrier.

Hypertension during pregnancy is a common occurrence that requires careful management. In normal pregnancies, blood pressure tends to decrease in the first trimester and then gradually increase to pre-pregnancy levels by term. However, in cases of hypertension during pregnancy, the systolic blood pressure is usually above 140 mmHg or the diastolic blood pressure is above 90 mmHg. Additionally, an increase of more than 30 mmHg systolic or 15 mmHg diastolic from the initial readings may also indicate hypertension.

There are three categories of hypertension during pregnancy: pre-existing hypertension, pregnancy-induced hypertension (PIH), and pre-eclampsia. Pre-existing hypertension refers to a history of hypertension before pregnancy or elevated blood pressure before 20 weeks gestation. PIH occurs in the second half of pregnancy and resolves after birth. Pre-eclampsia is characterized by hypertension and proteinuria, and may also involve edema.

The management of hypertension during pregnancy involves the use of antihypertensive medications such as labetalol, nifedipine, and hydralazine. In cases of pre-existing hypertension, ACE inhibitors and angiotensin II receptor blockers should be stopped immediately and alternative medications should be prescribed. Women who are at high risk of developing pre-eclampsia should take aspirin from 12 weeks until the birth of the baby. It is important to carefully monitor blood pressure and proteinuria levels during pregnancy to ensure the health of both the mother and the baby.

When a pregnant woman is exposed to chickenpox, the first step is to check for antibodies. Chickenpox is caused by a virus called varicella-zoster and can cause a range of symptoms including myalgia and headache, followed by a rash of small macules, clear vesicles, and pustules. The disease can be more severe in adults and can lead to complications such as pneumonia and secondary bacterial infections. In pregnant women, there is a risk of complications for the fetus, particularly after 36 weeks gestation. If a child is born within 7 days of the mother developing the rash, they are at increased risk of severe chickenpox and may require treatment. Significant exposure to chickenpox is defined as being in the same room for 15 minutes or more with someone who has the disease. If a pregnant woman is unsure of their chickenpox exposure, they should be tested for varicella-zoster IgG levels. If positive, they are immune, but if negative, further advice should be sought from obstetrics and gynecology. It is important to act promptly and seek medical advice if a pregnant woman displays any symptoms of chickenpox.

Chickenpox exposure in pregnancy can pose risks to both the mother and fetus, including fetal varicella syndrome. Post-exposure prophylaxis (PEP) with varicella-zoster immunoglobulin (VZIG) or antivirals should be given to non-immune pregnant women, with timing dependent on gestational age. If a pregnant woman develops chickenpox, specialist advice should be sought and oral aciclovir may be given if she is ≥ 20 weeks and presents within 24 hours of onset of the rash.

For women with risk factors for infertility, such as contralateral tube damage, salpingotomy should be considered as the preferred surgical management for ectopic pregnancy. In the case of this patient, who presented with acute-onset abdominal pain and vaginal bleeding 6-8 weeks after her last period, a positive pregnancy test, and ultrasound findings confirming ectopic pregnancy, surgical intervention is necessary. Given the size of the ectopic pregnancy and beta-hCG levels, either laparoscopic salpingectomy or salpingotomy is appropriate. However, since the patient has a history of PID and scarring of the contralateral tube, salpingotomy is the preferred option as it preserves the affected tube and her fertility. Expectant management, laparoscopic salpingectomy, and medical management with methotrexate are not appropriate for this patient’s case.

Ectopic pregnancy is a serious condition that requires prompt investigation and management. Women who are stable are typically investigated and managed in an early pregnancy assessment unit, while those who are unstable should be referred to the emergency department. The investigation of choice for ectopic pregnancy is a transvaginal ultrasound, which will confirm the presence of a positive pregnancy test.

There are three ways to manage ectopic pregnancies: expectant management, medical management, and surgical management. The choice of management will depend on various criteria, such as the size of the ectopic pregnancy, whether it is ruptured or not, and the patient’s symptoms and hCG levels. Expectant management involves closely monitoring the patient over 48 hours, while medical management involves giving the patient methotrexate and requires follow-up. Surgical management can involve salpingectomy or salpingotomy, depending on the patient’s risk factors for infertility.

Salpingectomy is the first-line treatment for women with no other risk factors for infertility, while salpingotomy should be considered for women with contralateral tube damage. However, around 1 in 5 women who undergo a salpingotomy require further treatment, such as methotrexate and/or a salpingectomy. It is important to carefully consider the patient’s individual circumstances and make a decision that will provide the best possible outcome.

Women need to start using contraception only 21 days after giving birth during the post-partum period. It is recommended that they begin taking the combined contraceptive pill three weeks after delivery. However, if they are breastfeeding, they should wait for six weeks before starting the pill.

After giving birth, women need to use contraception after 21 days. The progestogen-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first two days after day 21. A small amount of progestogen enters breast milk, but it is not harmful to the infant. On the other hand, the combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than six weeks post-partum. If breastfeeding is between six weeks and six months postpartum, it is a UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk post-partum. After day 21, additional contraception should be used for the first seven days. The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after four weeks.

The lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than six months post-partum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

When a couple is trying to conceive, it is normal for it to take up to one year for them to be successful. Therefore, medical examinations are typically conducted after one year of consistent attempts to conceive. However, it may be wise to address any physical barriers that could be hindering the couple’s ability to conceive, which is why their sexual history is taken into consideration.

Infertility is a common issue that affects approximately 1 in 7 couples. It is important to note that around 84% of couples who have regular sexual intercourse will conceive within the first year, and 92% within the first two years. The causes of infertility can vary, with male factor accounting for 30%, unexplained causes accounting for 20%, ovulation failure accounting for 20%, tubal damage accounting for 15%, and other causes accounting for the remaining 15%.

When investigating infertility, there are some basic tests that can be done. These include a semen analysis and a serum progesterone test. The serum progesterone test is done 7 days prior to the expected next period, typically on day 21 for a 28-day cycle. The interpretation of the serum progesterone level is as follows: if it is less than 16 nmol/l, it should be repeated and if it remains consistently low, referral to a specialist is necessary. If the level is between 16-30 nmol/l, it should be repeated, and if it is greater than 30 nmol/l, it indicates ovulation.

It is important to counsel patients on lifestyle factors that can impact fertility. This includes taking folic acid, maintaining a healthy BMI between 20-25, and advising regular sexual intercourse every 2 to 3 days. Additionally, patients should be advised to quit smoking and limit alcohol consumption to increase their chances of conceiving.

Oligohydramnios is a condition that occurs during pregnancy when there is a shortage of amniotic fluid. This can result in a smaller symphysiofundal height.

Oligohydramnios is a condition characterized by a decrease in the amount of amniotic fluid present in the womb. The definition of oligohydramnios varies, but it is generally considered to be present when there is less than 500ml of amniotic fluid at 32-36 weeks of gestation or an amniotic fluid index (AFI) that falls below the 5th percentile.

There are several potential causes of oligohydramnios, including premature rupture of membranes, Potter sequence, bilateral renal agenesis with pulmonary hypoplasia, intrauterine growth restriction, post-term gestation, and pre-eclampsia. These conditions can all contribute to a reduction in the amount of amniotic fluid present in the womb, which can have significant implications for fetal development and health. It is important for healthcare providers to monitor amniotic fluid levels and identify any potential causes of oligohydramnios in order to provide appropriate care and support for both the mother and the developing fetus.

Breast Mass Differential Diagnosis

Breast abscesses typically present with localised breast inflammation, pain, and fever. Treatment involves antibiotics and/or incision and drainage. Early breast cancer may be asymptomatic, but may present with changes in breast size or shape, skin dimpling, nipple abnormalities, and axillary lump. Fat necrosis is a benign inflammatory process that can result from trauma or surgery, and presents as a firm, painless mass. Fibroadenoma is the most common cause of breast mass in women aged <35 years, presenting as a singular, firm, rubbery, smooth, mobile, painless mass. Diffuse cystic mastopathy is characterised by cysts of varying sizes due to hormonal changes, but typically presents with multiple lumps and is not associated with inflammation. Clinical examination and biopsy may be needed to differentiate between these conditions.

If a woman who is pregnant lacks immunity to rubella, she should receive the MMR vaccine after giving birth.

In the absence of any indication that this pregnant woman has been exposed to rubella, she should avoid contact with individuals who may have the disease and receive the MMR vaccine after giving birth, as it cannot be administered during pregnancy. There is no recommended treatment for preventing rubella after exposure based on the clinical history. To prevent complications in future pregnancies, it is important to offer her the MMR vaccine.

Rubella and Pregnancy: Risks, Features, Diagnosis, and Management

Rubella, also known as German measles, is a viral infection caused by the togavirus. Thanks to the introduction of the MMR vaccine, it is now rare. However, if contracted during pregnancy, there is a risk of congenital rubella syndrome, which can cause serious harm to the fetus. It is important to note that the incubation period is 14-21 days, and individuals are infectious from 7 days before symptoms appear to 4 days after the onset of the rash.

The risk of damage to the fetus is highest in the first 8-10 weeks of pregnancy, with a risk as high as 90%. However, damage is rare after 16 weeks. Features of congenital rubella syndrome include sensorineural deafness, congenital cataracts, congenital heart disease (e.g. patent ductus arteriosus), growth retardation, hepatosplenomegaly, purpuric skin lesions, ‘salt and pepper’ chorioretinitis, microphthalmia, and cerebral palsy.

If a suspected case of rubella in pregnancy arises, it should be discussed immediately with the local Health Protection Unit (HPU) as type/timing of investigations may vary. IgM antibodies are raised in women recently exposed to the virus. It should be noted that it is very difficult to distinguish rubella from parvovirus B19 clinically. Therefore, it is important to also check parvovirus B19 serology as there is a 30% risk of transplacental infection, with a 5-10% risk of fetal loss.

If a woman is tested at any point and no immunity is demonstrated, they should be advised to keep away from people who might have rubella. Non-immune mothers should be offered the MMR vaccination in the post-natal period. However, MMR vaccines should not be administered to women known to be pregnant or attempting to become pregnant.

If a woman experiences pelvic pain during ovulation but does not have any vaginal bleeding, it may be Mittelschmerz. This type of pain is typically felt in the middle of the menstrual cycle. It is unlikely that a young patient with normal examination and intermittent abdominal pain during ovulation has ovarian malignancy. Additionally, there are no symptoms of hirsutism or changes to periods that suggest PCOS, nor are there any gastrointestinal symptoms that suggest IBS.

Understanding Mittelschmerz: Abdominal Pain Associated with Ovulation

Mittelschmerz, which translates to middle pain, is a type of abdominal pain that occurs during ovulation in approximately 20% of women. The exact cause of this mid-cycle pain is not fully understood, but there are several theories. One theory suggests that the pain is caused by the leakage of follicular fluid containing prostaglandins during ovulation. Another theory suggests that the growth of the follicle stretches the surface of the ovary, leading to pain.

The pain associated with Mittelschmerz typically presents suddenly in either iliac fossa and then spreads to the pelvic area. The pain is usually not severe and can last from minutes to hours. It is self-limiting and resolves within 24 hours of onset. The pain may switch sides from month to month, depending on the site of ovulation.

There are no specific tests to confirm Mittelschmerz, and it is diagnosed clinically after taking a full history and examination to exclude other conditions. Abdominal and pelvic examinations typically do not reveal any abnormal signs.

Mittelschmerz is not harmful and can be managed with simple analgesia. Understanding this condition can help women recognize and manage the pain associated with ovulation.

Premature Ovarian Insufficiency: Causes and Management

Premature ovarian insufficiency is a condition where menopausal symptoms and elevated gonadotrophin levels occur before the age of 40. It affects approximately 1 in 100 women and can be caused by various factors such as idiopathic reasons, family history, bilateral oophorectomy, radiotherapy, chemotherapy, infection, autoimmune disorders, and resistant ovary syndrome. The symptoms of premature ovarian insufficiency are similar to those of normal menopause, including hot flushes, night sweats, infertility, secondary amenorrhoea, raised FSH and LH levels, and low oestradiol.

Management of premature ovarian insufficiency involves hormone replacement therapy (HRT) or a combined oral contraceptive pill until the age of the average menopause, which is 51 years. It is important to note that HRT does not provide contraception in case spontaneous ovarian activity resumes. Early diagnosis and management of premature ovarian insufficiency can help alleviate symptoms and improve quality of life for affected women.

Postcoital bleeding is most commonly caused by cervical ectropion.

Understanding Postcoital Bleeding

Postcoital bleeding refers to vaginal bleeding that occurs after sexual intercourse. In approximately 50% of cases, no identifiable pathology is found. However, cervical ectropion is the most common identifiable cause, accounting for around 33% of cases. This condition is more prevalent in women who are taking the combined oral contraceptive pill. Other potential causes of postcoital bleeding include cervicitis, which may be due to Chlamydia infection, cervical cancer, polyps, and trauma.

Transverse myelitis is not linked to pre-eclampsia.

Pre-eclampsia is a condition that occurs during pregnancy and is characterized by high blood pressure, proteinuria, and edema. It can lead to complications such as eclampsia, neurological issues, fetal growth problems, liver involvement, and cardiac failure. Severe pre-eclampsia is marked by hypertension, proteinuria, headache, visual disturbances, and other symptoms. Risk factors for pre-eclampsia include hypertension in a previous pregnancy, chronic kidney disease, autoimmune disease, diabetes, chronic hypertension, first pregnancy, and age over 40. Aspirin may be recommended for women with high or moderate risk factors. Treatment involves emergency assessment, admission for observation, and medication such as labetalol, nifedipine, or hydralazine. Delivery of the baby is the most important step in management, with timing depending on the individual case.

Vaginal PGE2 is the preferred method of induction of labour, with other options such as emergency caesarean section, maternal oxytocin infusion, amniotomy, and cervical ripening balloon being considered only in certain situations. Women undergoing vaginal PGE2 should be aware of the risk of uterine hyperstimulation and may require additional analgesia. The cervix should be reassessed before considering oxytocin infusion. Amniotomy may be used in combination with oxytocin infusion in patients with a ripe cervix. Cervical ripening balloon should not be used as the primary method for induction of labour due to its potential pain, bleeding, and infection risks.

Induction of Labour: Reasons, Methods, and Complications

Induction of labour is a medical process that involves starting labour artificially. It is necessary in about 20% of pregnancies due to various reasons such as prolonged pregnancy, prelabour premature rupture of the membranes, diabetes, pre-eclampsia, and rhesus incompatibility. The Bishop score is used to assess whether induction of labour is required, which takes into account cervical position, consistency, effacement, dilation, and fetal station. A score of less than 5 indicates that labour is unlikely to start without induction, while a score of 8 or more indicates that the cervix is ripe and there is a high chance of spontaneous labour or response to interventions made to induce labour.

There are several methods of induction of labour, including membrane sweep, vaginal prostaglandin E2, maternal oxytocin infusion, amniotomy, and cervical ripening balloon. Membrane sweeping involves separating the chorionic membrane from the decidua by rotating the examining finger against the wall of the uterus. Vaginal prostaglandin E2 is the preferred method of induction of labour, unless there are specific clinical reasons for not using it. Uterine hyperstimulation is the main complication of induction of labour, which refers to prolonged and frequent uterine contractions that can cause fetal hypoxemia and acidemia. In rare cases, uterine rupture may occur, which requires removing the vaginal prostaglandins and stopping the oxytocin infusion if one has been started, and tocolysis with terbutaline.

Induction of Labour: Reasons, Methods, and Complications

Induction of labour is a medical process that involves starting labour artificially. It is necessary in about 20% of pregnancies due to various reasons such as prolonged pregnancy, prelabour premature rupture of the membranes, diabetes, pre-eclampsia, and rhesus incompatibility. The Bishop score is used to assess whether induction of labour is required, which takes into account cervical position, consistency, effacement, dilation, and fetal station. A score of less than 5 indicates that labour is unlikely to start without induction, while a score of 8 or more indicates that the cervix is ripe and there is a high chance of spontaneous labour or response to interventions made to induce labour.

There are several methods of induction of labour, including membrane sweep, vaginal prostaglandin E2, maternal oxytocin infusion, amniotomy, and cervical ripening balloon. Membrane sweeping involves separating the chorionic membrane from the decidua by rotating the examining finger against the wall of the uterus. Vaginal prostaglandin E2 is the preferred method of induction of labour, unless there are specific clinical reasons for not using it. Uterine hyperstimulation is the main complication of induction of labour, which refers to prolonged and frequent uterine contractions that can cause fetal hypoxemia and acidemia. In rare cases, uterine rupture may occur, which requires removing the vaginal prostaglandins and stopping the oxytocin infusion if one has been started, and tocolysis with terbutaline.

The use of combined oral contraceptive pills is completely contraindicated in patients with migraine with aura due to an increased risk of ischaemic stroke (UKMEC class 4). However, progestogen-based contraception methods and the levonorgestrel-releasing intrauterine device are considered safe (UKMEC 2) as the benefits of using these methods outweigh the potential risks. The copper intrauterine device is the only form of contraception recommended by UKMEC as having no contraindication in this condition (UKMEC 1).

Intrauterine contraceptive devices include copper IUDs and levonorgestrel-releasing IUS. Both are over 99% effective. The IUD prevents fertilization by decreasing sperm motility, while the IUS prevents endometrial proliferation and thickens cervical mucus. Potential problems include heavier periods with IUDs and initial bleeding with the IUS. There is a small risk of uterine perforation, ectopic pregnancy, and infection. New IUS systems, such as Jaydess® and Kyleena®, have smaller frames and less levonorgestrel, resulting in lower serum levels and different rates of amenorrhea.

Gonorrhoea is best treated with intramuscular ceftriaxone.

Understanding Gonorrhoea: Causes, Symptoms, Microbiology, and Management

Gonorrhoea is a sexually transmitted infection caused by the Gram-negative diplococcus Neisseria gonorrhoeae. It can occur on any mucous membrane surface, including the genitourinary tract, rectum, and pharynx. The incubation period of gonorrhoea is typically 2-5 days. Symptoms in males include urethral discharge and dysuria, while females may experience cervicitis leading to vaginal discharge. Rectal and pharyngeal infections are usually asymptomatic.

Immunisation against gonorrhoea is not possible, and reinfection is common due to antigen variation of type IV pili and Opa proteins. Local complications may develop, including urethral strictures, epididymitis, and salpingitis, which can lead to infertility. Disseminated infection may also occur, with gonococcal infection being the most common cause of septic arthritis in young adults.

Management of gonorrhoea involves the use of antibiotics. Ciprofloxacin used to be the treatment of choice, but there is now increased resistance to it. Cephalosporins are now more widely used, with a single dose of IM ceftriaxone 1g being the new first-line treatment. If ceftriaxone is refused, oral cefixime 400mg + oral azithromycin 2g should be used. Disseminated gonococcal infection (DGI) and gonococcal arthritis may also occur, with symptoms including tenosynovitis, migratory polyarthritis, and dermatitis. Later complications include septic arthritis, endocarditis, and perihepatitis.

Understanding Lyme Disease

Lyme disease is a bacterial infection caused by Borrelia burgdorferi and is transmitted through tick bites. The early symptoms of Lyme disease include erythema migrans, a characteristic bulls-eye rash that appears at the site of the tick bite. This rash is painless, slowly increases in size, and can be more than 5 cm in diameter. Other early symptoms include headache, lethargy, fever, and joint pain.

If erythema migrans is present, Lyme disease can be diagnosed clinically, and antibiotics should be started immediately. The first-line test for Lyme disease is an enzyme-linked immunosorbent assay (ELISA) to detect antibodies to Borrelia burgdorferi. If the ELISA is negative but Lyme disease is still suspected, it should be repeated 4-6 weeks later. If Lyme disease is suspected in patients who have had symptoms for 12 weeks or more, an immunoblot test should be done.

Tick bites can cause significant anxiety, but routine antibiotic treatment is not recommended by NICE. If the tick is still present, it should be removed using fine-tipped tweezers, and the area should be washed. In cases of suspected or confirmed Lyme disease, doxycycline is the preferred treatment for early disease, while ceftriaxone is used for disseminated disease. A Jarisch-Herxheimer reaction may occur after initiating therapy, which can cause fever, rash, and tachycardia.

In summary, Lyme disease is a bacterial infection transmitted through tick bites. Early symptoms include erythema migrans, headache, lethargy, fever, and joint pain. Diagnosis is made through clinical presentation and ELISA testing, and treatment involves antibiotics. Tick bites do not require routine antibiotic treatment, and ticks should be removed using fine-tipped tweezers.

If two combined oral contraceptive pills (COCPs) are missed in week three, the woman should finish the remaining pills in the current pack and immediately start a new pack without taking the pill-free interval. It is important to note that contraceptive protection may be reduced during this time. Seeking emergency contraception is not necessary if there has been no unprotected sexual intercourse during the period of missed pills. Simply taking an active pill and continuing with the upcoming pill-free interval is not sufficient as the woman has likely lost contraceptive protection during the missed pill days. Taking an active pill as soon as possible without exercising caution is also not recommended as the woman may have reduced contraceptive protection.

Missed Pills in Combined Oral Contraceptive Pill

When taking a combined oral contraceptive (COC) pill containing 30-35 micrograms of ethinylestradiol, it is important to know what to do if a pill is missed. The Faculty of Sexual and Reproductive Healthcare (FSRH) has updated their recommendations in recent years. If one pill is missed at any time in the cycle, the woman should take the last pill even if it means taking two pills in one day and then continue taking pills daily, one each day. No additional contraceptive protection is needed in this case.

However, if two or more pills are missed, the woman should take the last pill even if it means taking two pills in one day, leave any earlier missed pills, and then continue taking pills daily, one each day. In this case, the woman should use condoms or abstain from sex until she has taken pills for 7 days in a row. If pills are missed in week 1 (Days 1-7), emergency contraception should be considered if she had unprotected sex in the pill-free interval or in week 1. If pills are missed in week 2 (Days 8-14), after seven consecutive days of taking the COC there is no need for emergency contraception.

If pills are missed in week 3 (Days 15-21), the woman should finish the pills in her current pack and start a new pack the next day, thus omitting the pill-free interval. Theoretically, women would be protected if they took the COC in a pattern of 7 days on, 7 days off. It is important to follow these guidelines to ensure the effectiveness of the COC in preventing pregnancy.

The FSRH uses a scale of 1 to 4 to categorize risk factors for contraceptive methods. A rating of 1 indicates no restrictions on use, while a rating of 4 indicates a condition that poses an unacceptable risk if the contraceptive method is used. Migraine with aura is the only absolute contraindication among the answer options. Ratings of 2 and 3 indicate that the advantages and risks of the contraceptive method should be carefully considered and evaluated by a clinical expert.

The decision to prescribe the combined oral contraceptive pill is now based on the UK Medical Eligibility Criteria (UKMEC), which categorizes potential contraindications and cautions on a four-point scale. UKMEC 1 indicates no restrictions for use, while UKMEC 2 suggests that the benefits outweigh the risks. UKMEC 3 indicates that the disadvantages may outweigh the advantages, and UKMEC 4 represents an unacceptable health risk. Examples of UKMEC 3 conditions include controlled hypertension, a family history of thromboembolic disease in first-degree relatives under 45 years old, and current gallbladder disease. Examples of UKMEC 4 conditions include a history of thromboembolic disease or thrombogenic mutation, breast cancer, and uncontrolled hypertension. Diabetes mellitus diagnosed over 20 years ago is classified as UKMEC 3 or 4 depending on severity. In 2016, breast feeding between 6 weeks and 6 months postpartum was changed from UKMEC 3 to UKMEC 2.

The recommended first-line treatment for menorrhagia is the intra-uterine system (IUS), which has a high success rate in stopping bleeding and only requires one insertion procedure. Additionally, it provides reliable contraception. Conversely, the copper coil may exacerbate menorrhagia symptoms. While medication such as the progesterone-only pill or combined oral contraceptive pill can be used, they are not the first choice. It would be an extreme measure to refer a woman of child-bearing age for a hysterectomy, especially when there are less invasive and reversible options available to treat menorrhagia, even if the patient expresses no desire for children.

Managing Heavy Menstrual Bleeding

Heavy menstrual bleeding, also known as menorrhagia, is a condition where a woman experiences excessive blood loss during her menstrual cycle. While it was previously defined as total blood loss of over 80 ml per cycle, the management of menorrhagia now depends on the woman’s perception of what is excessive. In the past, hysterectomy was a common treatment for heavy periods, but the approach has changed significantly since the 1990s.

To manage menorrhagia, a full blood count should be performed in all women. If symptoms suggest a structural or histological abnormality, a routine transvaginal ultrasound scan should be arranged. For women who do not require contraception, mefenamic acid or tranexamic acid can be used. If there is no improvement, other drugs can be tried while awaiting referral.

For women who require contraception, options include the intrauterine system (Mirena), combined oral contraceptive pill, and long-acting progestogens. Norethisterone can also be used as a short-term option to rapidly stop heavy menstrual bleeding. The flowchart below shows the management of menorrhagia.

[Insert flowchart here]

Bacterial vaginosis during pregnancy can lead to various pregnancy-related issues, such as preterm labor. In the past, it was advised to avoid taking oral metronidazole during the first trimester. However, current guidelines suggest that it is safe to use throughout the entire pregnancy. For more information, please refer to the Clinical Knowledge Summary provided.

Bacterial vaginosis (BV) is a condition where there is an overgrowth of anaerobic organisms, particularly Gardnerella vaginalis, in the vagina. This leads to a decrease in the amount of lactobacilli, which produce lactic acid, resulting in an increase in vaginal pH. BV is not a sexually transmitted infection, but it is commonly seen in sexually active women. Symptoms include a fishy-smelling vaginal discharge, although some women may not experience any symptoms at all. Diagnosis is made using Amsel’s criteria, which includes the presence of thin, white discharge, clue cells on microscopy, a vaginal pH greater than 4.5, and a positive whiff test. Treatment involves oral metronidazole for 5-7 days, with a cure rate of 70-80%. However, relapse rates are high, with over 50% of women experiencing a recurrence within 3 months. Topical metronidazole or clindamycin may be used as alternatives.

Bacterial vaginosis during pregnancy can increase the risk of preterm labor, low birth weight, chorioamnionitis, and late miscarriage. It was previously recommended to avoid oral metronidazole in the first trimester and use topical clindamycin instead. However, recent guidelines suggest that oral metronidazole can be used throughout pregnancy. The British National Formulary (BNF) still advises against using high-dose metronidazole regimes. Clue cells, which are vaginal epithelial cells covered with bacteria, can be seen on microscopy in women with BV.

Adenomyosis is the condition where the tissue lining the uterus (endometrium) grows into the muscular wall of the uterus (myometrium).

Dysmenorrhoea is a condition where women experience excessive pain during their menstrual period. There are two types of dysmenorrhoea: primary and secondary. Primary dysmenorrhoea affects up to 50% of menstruating women and is not caused by any underlying pelvic pathology. It usually appears within 1-2 years of the menarche and is thought to be partially caused by excessive endometrial prostaglandin production. Symptoms include suprapubic cramping pains that may radiate to the back or down the thigh, and pain typically starts just before or within a few hours of the period starting. NSAIDs such as mefenamic acid and ibuprofen are effective in up to 80% of women, and combined oral contraceptive pills are used second line for management.

Secondary dysmenorrhoea, on the other hand, typically develops many years after the menarche and is caused by an underlying pathology. The pain usually starts 3-4 days before the onset of the period. Causes of secondary dysmenorrhoea include endometriosis, adenomyosis, pelvic inflammatory disease, intrauterine devices, and fibroids. Clinical Knowledge Summaries recommend referring all patients with secondary dysmenorrhoea to gynaecology for investigation. It is important to note that the intrauterine system (Mirena) may help dysmenorrhoea, but this only applies to normal copper coils.

The most likely diagnosis for this patient is androgen insensitivity syndrome (AIS). This is because she has not started menstruating by the age of 15, has little to no axillary or pubic hair, and elevated testosterone levels. These symptoms are all indicative of AIS, which is a genetic condition where individuals with male chromosomes (46XY) have a female appearance due to their body’s resistance to testosterone. The lower pelvic masses seen on examination are likely to be undescended testes.

Congenital adrenal hyperplasia (CAH) is an unlikely diagnosis as it typically causes excess male-pattern hair growth, including axillary and pubic hair, which is not seen in this patient. Additionally, CAH would not explain the presence of the lower pelvic masses.

Functional hypothalamic amenorrhoea is also unlikely as this condition is typically associated with low body weight, which is not the case for this patient. Furthermore, her FSH and LH levels are within the normal range, indicating that there is no hypothalamic dysfunction.

Polycystic ovarian syndrome (PCOS) is an unlikely diagnosis as it typically causes irregular periods rather than a complete absence of menstruation. Additionally, patients with PCOS often have excessive hair growth, which is not seen in this patient. PCOS would also not explain the presence of the lower pelvic masses.

Understanding Androgen Insensitivity Syndrome

Androgen insensitivity syndrome is a genetic condition that affects individuals with an XY genotype, causing them to develop a female phenotype due to their body’s resistance to testosterone. This condition was previously known as testicular feminization syndrome. The main features of this condition include primary amenorrhea, little or no pubic and axillary hair, undescended testes leading to groin swellings, and breast development due to the conversion of testosterone to estrogen.

Diagnosis of androgen insensitivity syndrome can be made through a buccal smear or chromosomal analysis, which reveals a 46XY genotype. After puberty, testosterone levels in affected individuals are typically in the high-normal to slightly elevated range for postpubertal boys.

Management of androgen insensitivity syndrome involves counseling and raising the child as female. Bilateral orchidectomy is recommended to reduce the risk of testicular cancer due to undescended testes. Additionally, estrogen therapy may be used to promote the development of secondary sexual characteristics.

In summary, androgen insensitivity syndrome is a genetic condition that affects the development of individuals with an XY genotype, causing them to develop a female phenotype. Early diagnosis and management can help affected individuals lead healthy and fulfilling lives.

Contraception is still necessary after menopause. Women who are over 50 years old should use contraception for at least 12 months after their last period, while those under 50 years old should use it for at least 24 months after their last period.

Understanding Menopause and Contraception

Menopause is a natural biological process that marks the end of a woman’s reproductive years. On average, women in the UK experience menopause at the age of 51. However, prior to menopause, women may experience a period known as the climacteric. During this time, ovarian function starts to decline, and women may experience symptoms such as hot flashes, mood swings, and vaginal dryness.

It is important for women to understand that they can still become pregnant during the climacteric period. Therefore, it is recommended to use effective contraception until a certain period of time has passed. Women over the age of 50 should use contraception for 12 months after their last period, while women under the age of 50 should use contraception for 24 months after their last period. By understanding menopause and the importance of contraception during the climacteric period, women can make informed decisions about their reproductive health.

Pregnant women who contract chickenpox after 20 weeks of gestation should seek medical attention immediately. This is because chickenpox can lead to serious complications such as pneumonia, hepatitis, and encephalitis. Treatment with oral aciclovir is recommended if the woman presents within 24 hours of developing the rash. Aciclovir can help reduce the duration of fever and other symptoms. Symptomatic treatment can also be used alongside aciclovir. If the chickenpox is severe, the woman should be referred to the hospital for intravenous aciclovir. Additionally, a referral to fetal medicine may be necessary due to the small risk of fetal varicella syndrome in the first 28 weeks of pregnancy. It is important to advise anyone with chickenpox to avoid contact with pregnant women and neonates until all lesions have crusted over, which usually takes about 5 days after the onset of the rash. VZIG has no therapeutic benefit once the rash has started. These guidelines are based on the RCOG Greentop guidelines for chickenpox in pregnancy.

Chickenpox exposure in pregnancy can pose risks to both the mother and fetus, including fetal varicella syndrome. Post-exposure prophylaxis (PEP) with varicella-zoster immunoglobulin (VZIG) or antivirals should be given to non-immune pregnant women, with timing dependent on gestational age. If a pregnant woman develops chickenpox, specialist advice should be sought and oral aciclovir may be given if she is ≥ 20 weeks and presents within 24 hours of onset of the rash.

Breast cancer risk is increased by HRT, early menarche, late menopause, and COCP, while it is reduced by multiple pregnancy and breastfeeding.

Breast Cancer Risk Factors: Understanding the Predisposing Factors

Breast cancer is a complex disease that can be influenced by various factors. Some of these factors are considered predisposing factors, which means they increase the likelihood of developing breast cancer. One of the most well-known predisposing factors is the presence of BRCA1 and BRCA2 genes, which can increase a person’s lifetime risk of breast and ovarian cancer by 40%. Other predisposing factors include having a first-degree relative with premenopausal breast cancer, nulliparity, having a first pregnancy after the age of 30, early menarche, late menopause, combined hormone replacement therapy, combined oral contraceptive use, past breast cancer, not breastfeeding, ionizing radiation, p53 gene mutations, obesity, and previous surgery for benign disease.

To reduce the risk of developing breast cancer, it is important to understand these predisposing factors and take steps to minimize their impact. For example, women with a family history of breast cancer may choose to undergo genetic testing to determine if they carry the BRCA1 or BRCA2 genes. Women who have not yet had children may consider having their first child before the age of 30, while those who have already had children may choose to breastfeed. Additionally, women who are considering hormone replacement therapy or oral contraceptives should discuss the potential risks and benefits with their healthcare provider. By understanding these predisposing factors and taking proactive steps to reduce their impact, women can help protect themselves against breast cancer.

Pregnant women with symptomatic bacterial vaginosis (BV) should be offered treatment using oral metronidazole. If BV is incidentally detected in a pregnant woman without symptoms, it is advisable to discuss with her obstetrician whether treatment is necessary. High-dose regimens are not recommended during pregnancy. In case the woman prefers a topical treatment or is unable to tolerate oral metronidazole, intravaginal metronidazole gel or clindamycin cream can be used as alternative choices. However, oral clindamycin is not widely recommended in primary care due to the increased risk of pseudomembranous colitis. This information is sourced from NICE CKS – Bacterial Vaginosis.

Bacterial vaginosis (BV) is a condition where there is an overgrowth of anaerobic organisms, particularly Gardnerella vaginalis, in the vagina. This leads to a decrease in the amount of lactobacilli, which produce lactic acid, resulting in an increase in vaginal pH. BV is not a sexually transmitted infection, but it is commonly seen in sexually active women. Symptoms include a fishy-smelling vaginal discharge, although some women may not experience any symptoms at all. Diagnosis is made using Amsel’s criteria, which includes the presence of thin, white discharge, clue cells on microscopy, a vaginal pH greater than 4.5, and a positive whiff test. Treatment involves oral metronidazole for 5-7 days, with a cure rate of 70-80%. However, relapse rates are high, with over 50% of women experiencing a recurrence within 3 months. Topical metronidazole or clindamycin may be used as alternatives.

Bacterial vaginosis during pregnancy can increase the risk of preterm labor, low birth weight, chorioamnionitis, and late miscarriage. It was previously recommended to avoid oral metronidazole in the first trimester and use topical clindamycin instead. However, recent guidelines suggest that oral metronidazole can be used throughout pregnancy. The British National Formulary (BNF) still advises against using high-dose metronidazole regimes. Clue cells, which are vaginal epithelial cells covered with bacteria, can be seen on microscopy in women with BV.

When there is excessive menstrual bleeding without any underlying medical condition, it is referred to as dysfunctional uterine bleeding. Endometriosis typically causes pain a few days before menstruation and painful intercourse. The absence of fibroids and polyps is indicated by a normal ultrasound scan, and this condition is more prevalent in older women. Although a clotting disorder must be ruled out, the blood test results suggest that it is improbable.

Understanding Menorrhagia: Causes and Definition

Menorrhagia is a condition characterized by heavy menstrual bleeding. While it was previously defined as total blood loss exceeding 80 ml per menstrual cycle, the assessment and management of the condition now focuses on the woman’s perception of excessive bleeding and its impact on her quality of life. Dysfunctional uterine bleeding, which occurs in the absence of underlying pathology, is the most common cause of menorrhagia, accounting for about half of all cases. Anovulatory cycles, uterine fibroids, hypothyroidism, pelvic inflammatory disease, and bleeding disorders such as von Willebrand disease are other potential causes of menorrhagia. It is important to note that the use of intrauterine devices, specifically copper coils, may also contribute to heavy menstrual bleeding. However, the intrauterine system (Mirena) is a treatment option for menorrhagia.

GBS bacteriuria is linked to an increased risk of chorioamnionitis and neonatal sepsis, therefore, the Royal College of Obstetricians and Gynaecologists recommends that women with GBS bacteriuria should receive intrapartum antibiotics along with appropriate treatment upon diagnosis. In cases where the patient is not allergic to penicillin, intravenous benzylpenicillin should be administered as soon as possible after the onset of labor and then every 4 hours until delivery. Postnatal antibiotic treatment is not necessary unless there are indications of neonatal infection. Caesarean section is not recommended. [RCOG Green-top Guideline No. 36]

Group B Streptococcus (GBS) is a common cause of severe infection in newborns. It is estimated that 20-40% of mothers carry GBS in their bowel flora, which can be passed on to their infants during labor and lead to serious infections. Prematurity, prolonged rupture of membranes, previous sibling GBS infection, and maternal pyrexia are all risk factors for GBS infection. The Royal College of Obstetricians and Gynaecologists (RCOG) has published guidelines on GBS management, which include not offering universal screening for GBS to all women and not offering screening based on maternal request. Women who have had GBS detected in a previous pregnancy should be offered intrapartum antibiotic prophylaxis (IAP) or testing in late pregnancy and antibiotics if still positive. IAP should also be offered to women with a previous baby with GBS disease, women in preterm labor, and women with a fever during labor. Benzylpenicillin is the preferred antibiotic for GBS prophylaxis.

During pregnancy, women are checked for anaemia twice – once at the initial booking visit (usually around 8-10 weeks) and again at 28 weeks. The National Institute for Health and Care Excellence (NICE) has set specific cut-off levels to determine if a pregnant woman requires oral iron therapy. These levels are less than 110 g/L in the first trimester, less than 105 g/L in the second and third trimesters, and less than 100 g/L postpartum.

If a woman’s iron levels fall below these cut-offs, she will be prescribed oral ferrous sulfate or ferrous fumarate. It is important to continue this treatment for at least three months after the iron deficiency has been corrected to allow the body to replenish its iron stores. By following these guidelines, healthcare professionals can help ensure that pregnant women receive the appropriate care to prevent and manage anaemia during pregnancy.

Category 2 caesarean sections should be performed within 75 minutes of the decision being made. This is because these cases involve maternal or fetal compromise that is not immediately life-threatening, allowing the medical team to manage the emergency and plan the surgery to minimize risks to both the mother and the baby. A timeframe of 2 hours is incorrect as it would delay the necessary intervention. On the other hand, a timeframe of 30 minutes is only applicable to category 1 caesarean sections, where there is an immediate threat to the life of the mother or baby. A timeframe of 5 minutes is too short and may increase the risk of errors during the procedure.

Caesarean Section: Types, Indications, and Risks

Caesarean section, also known as C-section, is a surgical procedure that involves delivering a baby through an incision in the mother’s abdomen and uterus. In recent years, the rate of C-section has increased significantly due to an increased fear of litigation. There are two main types of C-section: lower segment C-section, which comprises 99% of cases, and classic C-section, which involves a longitudinal incision in the upper segment of the uterus.

C-section may be indicated for various reasons, including absolute cephalopelvic disproportion, placenta praevia grades 3/4, pre-eclampsia, post-maturity, IUGR, fetal distress in labor/prolapsed cord, failure of labor to progress, malpresentations, placental abruption, vaginal infection, and cervical cancer. The urgency of C-section may be categorized into four categories, with Category 1 being the most urgent and Category 4 being elective.

It is important for clinicians to inform women of the serious and frequent risks associated with C-section, including emergency hysterectomy, need for further surgery, admission to intensive care unit, thromboembolic disease, bladder injury, ureteric injury, and death. C-section may also increase the risk of uterine rupture, antepartum stillbirth, placenta praevia, and placenta accreta in subsequent pregnancies. Other complications may include persistent wound and abdominal discomfort, increased risk of repeat C-section, readmission to hospital, haemorrhage, infection, and fetal lacerations.

Vaginal birth after C-section (VBAC) may be an appropriate method of delivery for pregnant women with a single previous C-section delivery, except for those with previous uterine rupture or classical C-section scar. The success rate of VBAC is around 70-75%.

Contraceptives – Time to become effective (if not used on the first day of period):
Immediate: IUD
2 days: Progestin-only pill (POP)
7 days: Combined oral contraceptive (COC), injection, implant, intrauterine system (IUS)

Counselling for Women Considering the Progestogen-Only Pill

Women who are considering taking the progestogen-only pill (POP) should receive counselling on various aspects of the medication. One of the most common potential adverse effects is irregular vaginal bleeding. When starting the POP, immediate protection is provided if it is commenced up to and including day 5 of the cycle. If it is started later, additional contraceptive methods such as condoms should be used for the first 2 days. If switching from a combined oral contraceptive (COC), immediate protection is provided if the POP is continued directly from the end of a pill packet.

It is important to take the POP at the same time every day, without a pill-free break, unlike the COC. If a pill is missed by less than 3 hours, it should be taken as normal. If it is missed by more than 3 hours, the missed pill should be taken as soon as possible, and extra precautions such as condoms should be used until pill taking has been re-established for 48 hours. Diarrhoea and vomiting do not affect the POP, but assuming pills have been missed and following the above guidelines is recommended. Antibiotics have no effect on the POP, unless they alter the P450 enzyme system, such as rifampicin. Liver enzyme inducers may reduce the effectiveness of the POP.

In addition to these specific guidelines, women should also have a discussion on sexually transmitted infections (STIs) when considering the POP. It is important for women to receive comprehensive counselling on the POP to ensure they are aware of its potential effects and how to use it effectively.

It was once believed that taking antibiotics while on any form of contraceptive pill could reduce the pill’s effectiveness. However, it is now known that broad-spectrum antibiotics do not interact with the progesterone-only pill, and therefore no extra precautions are necessary. The only exception is enzyme-inducing antibiotics like rifampicin, which may affect the pill’s efficacy. Additionally, if an antibiotic causes vomiting or diarrhea, it may also affect the pill’s effectiveness, but this is true for any form of vomiting or diarrhea. Therefore, the correct advice is to reassure patients that no additional precautions are needed. Advising the use of barrier contraceptives or ceasing the pill is incorrect, as there is no evidence to support these actions.

Counselling for Women Considering the Progestogen-Only Pill

Women who are considering taking the progestogen-only pill (POP) should receive counselling on various aspects of the medication. One of the most common potential adverse effects is irregular vaginal bleeding. When starting the POP, immediate protection is provided if it is commenced up to and including day 5 of the cycle. If it is started later, additional contraceptive methods such as condoms should be used for the first 2 days. If switching from a combined oral contraceptive (COC), immediate protection is provided if the POP is continued directly from the end of a pill packet.

It is important to take the POP at the same time every day, without a pill-free break, unlike the COC. If a pill is missed by less than 3 hours, it should be taken as normal. If it is missed by more than 3 hours, the missed pill should be taken as soon as possible, and extra precautions such as condoms should be used until pill taking has been re-established for 48 hours. Diarrhoea and vomiting do not affect the POP, but assuming pills have been missed and following the above guidelines is recommended. Antibiotics have no effect on the POP, unless they alter the P450 enzyme system, such as rifampicin. Liver enzyme inducers may reduce the effectiveness of the POP.

In addition to these specific guidelines, women should also have a discussion on sexually transmitted infections (STIs) when considering the POP. It is important for women to receive comprehensive counselling on the POP to ensure they are aware of its potential effects and how to use it effectively.

Contraceptives – Time to become effective (if not used on the first day of period):
Immediate: IUD
2 days: Progestin-only pill (POP)
7 days: Combined oral contraceptive (COC), injection, implant, intrauterine system (IUS)

Intrauterine contraceptive devices include copper IUDs and levonorgestrel-releasing IUS. Both are over 99% effective. The IUD prevents fertilization by decreasing sperm motility, while the IUS prevents endometrial proliferation and thickens cervical mucus. Potential problems include heavier periods with IUDs and initial bleeding with the IUS. There is a small risk of uterine perforation, ectopic pregnancy, and infection. New IUS systems, such as Jaydess® and Kyleena®, have smaller frames and less levonorgestrel, resulting in lower serum levels and different rates of amenorrhea.

The use of COCP is absolutely contraindicated for individuals who are over 35 years old and smoke more than 15 cigarettes per day. Migraine without aura is not a contraindication, but migraine with aura is a UKMEC 3 contraindication. A BMI of over 35 kg/m2 and a family history of thromboembolism at age less than 45 years are also UKMEC 3 contraindications, but in this case, the patient’s BMI is 25 kg/m2 and her mother had pulmonary embolism at the age of 60 years, so these are not contraindications. Breastfeeding less than 6 weeks post-partum is a UKMEC 4 contraindication, but since the patient is 10 weeks post-partum, it is a UKMEC 2.

The decision to prescribe the combined oral contraceptive pill is now based on the UK Medical Eligibility Criteria (UKMEC), which categorizes potential contraindications and cautions on a four-point scale. UKMEC 1 indicates no restrictions for use, while UKMEC 2 suggests that the benefits outweigh the risks. UKMEC 3 indicates that the disadvantages may outweigh the advantages, and UKMEC 4 represents an unacceptable health risk. Examples of UKMEC 3 conditions include controlled hypertension, a family history of thromboembolic disease in first-degree relatives under 45 years old, and current gallbladder disease. Examples of UKMEC 4 conditions include a history of thromboembolic disease or thrombogenic mutation, breast cancer, and uncontrolled hypertension. Diabetes mellitus diagnosed over 20 years ago is classified as UKMEC 3 or 4 depending on severity. In 2016, breast feeding between 6 weeks and 6 months postpartum was changed from UKMEC 3 to UKMEC 2.

Women who have recently given birth, whether they are breastfeeding or not, can begin taking the progesterone-only pill at any time postpartum.

It is safe to use progesterone-only pills while breastfeeding, and there is no need to wait for a specific amount of time before starting them. If the pills are started after 21 days, it is recommended to use additional protection for the first 2 days. However, if the woman starts taking the pills immediately, there is no need for extra protection.

Delaying the start of progesterone-only pills can increase the risk of unwanted pregnancy. Therefore, it is important to begin taking them as soon as possible, regardless of whether the woman is breastfeeding or not.

In summary, there is no contraindication to starting progesterone-only pills during the first 21 days postpartum, and breastfeeding does not affect the decision to start them. Women can continue breastfeeding while taking these pills.

After giving birth, women need to use contraception after 21 days. The progestogen-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first two days after day 21. A small amount of progestogen enters breast milk, but it is not harmful to the infant. On the other hand, the combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than six weeks post-partum. If breastfeeding is between six weeks and six months postpartum, it is a UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk post-partum. After day 21, additional contraception should be used for the first seven days. The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after four weeks.

The lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than six months post-partum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

Screening for cervical cancer

Cervical Cancer Screening in the UK

Cervical cancer screening is a well-established program in the UK that aims to detect pre-malignant changes in the cervix. This program is estimated to prevent 1,000-4,000 deaths per year. However, it should be noted that around 15% of cervical adenocarcinomas are frequently undetected by screening.

The screening program has evolved significantly in recent years. Initially, smears were examined for signs of dyskaryosis, which may indicate cervical intraepithelial neoplasia. However, the introduction of HPV testing allowed for further risk stratification, and the NHS has now moved to an HPV first system. This means that a sample is tested for high-risk strains of human papillomavirus (hrHPV) first, and cytological examination is only performed if this is positive.

All women between the ages of 25-64 years are offered a smear test. Women aged 25-49 years are screened every three years, while those aged 50-64 years are screened every five years. However, cervical screening cannot be offered to women over 64. In Scotland, screening is offered from 25-64 every five years.

In special situations, cervical screening in pregnancy is usually delayed until three months post-partum, unless there are missed screenings or previous abnormal smears. Women who have never been sexually active have a very low risk of developing cervical cancer and may wish to opt-out of screening.

It is recommended to take a cervical smear around mid-cycle, although there is limited evidence to support this advice. Overall, the UK’s cervical cancer screening program is an essential tool in preventing cervical cancer and promoting women’s health.

Intrauterine contraceptive devices include copper IUDs and levonorgestrel-releasing IUS. Both are over 99% effective. The IUD prevents fertilization by decreasing sperm motility, while the IUS prevents endometrial proliferation and thickens cervical mucus. Potential problems include heavier periods with IUDs and initial bleeding with the IUS. There is a small risk of uterine perforation, ectopic pregnancy, and infection. New IUS systems, such as Jaydess® and Kyleena®, have smaller frames and less levonorgestrel, resulting in lower serum levels and different rates of amenorrhea.

Fertility Management in Men: Appropriate Investigations and Management Options

When it comes to fertility management in men, it is important to follow the guidelines set by the National Institute for Health and Care Excellence (NICE). According to NICE, couples who have been trying to conceive for a year with regular intercourse should be referred to fertility services. However, earlier investigation may be necessary if there is an underlying medical reason for conception difficulties. This means that watching and waiting for 12 months is the appropriate management option in most cases.

One of the investigations that may be necessary is a semen analysis, which is indicated after a year of trying to conceive. Testicular biopsy, on the other hand, is only necessary if there is a potential testicular carcinoma or for sperm retrieval for in-vitro fertilisation (IVF) procedures.

While screening for anti-sperm antibodies may be necessary in secondary care, it is not usually arranged in primary care. Similarly, screening for gonorrhoea is not part of the investigations for reduced fertility as it does not have a significant effect on a patient’s ability to conceive and is not usually asymptomatic. However, excluding asymptomatic chlamydia infection is an important part of the investigation for patients who are struggling with reduced fertility.

For patients with active hormone-responsive breast cancer, hormonal methods like HRT and tibolone are not recommended. Instead, non-hormonal methods like selective serotonin reuptake inhibitors and venlafaxine may be used to alleviate vasomotor symptoms of menopause. Topical estrogen can also be used to alleviate symptoms of vaginal atrophy, but it does not help with vasomotor symptoms. COCP is not a suitable treatment for menopausal symptoms.

Managing Menopause: Lifestyle Modifications, Hormone Replacement Therapy, and Non-Hormone Replacement Therapy

Menopause is a natural biological process that marks the end of a woman’s reproductive years. It is diagnosed when a woman has not had a period for 12 consecutive months. Menopausal symptoms are common and can last for up to 7 years, with varying degrees of severity and duration. The management of menopause can be divided into three categories: lifestyle modifications, hormone replacement therapy (HRT), and non-hormone replacement therapy.

Lifestyle modifications can help manage menopausal symptoms such as hot flushes, sleep disturbance, mood changes, and cognitive symptoms. Regular exercise, weight loss, stress reduction, and good sleep hygiene are recommended. For women who cannot or do not want to take HRT, non-hormonal treatments such as fluoxetine, citalopram, or venlafaxine for vasomotor symptoms, vaginal lubricants or moisturizers for vaginal dryness, and cognitive behavior therapy or antidepressants for psychological symptoms can be prescribed.

HRT is a treatment option for women with moderate to severe menopausal symptoms. However, it is contraindicated in women with current or past breast cancer, any estrogen-sensitive cancer, undiagnosed vaginal bleeding, or untreated endometrial hyperplasia. HRT brings certain risks, including venous thromboembolism, stroke, coronary heart disease, breast cancer, and ovarian cancer. Women should be advised of these risks and the fact that symptoms typically last for 2-5 years.

When stopping HRT, it is important to gradually reduce the dosage to limit recurrence of symptoms in the short term. However, in the long term, there is no difference in symptom control. Women who experience ineffective treatment, ongoing side effects, or unexplained bleeding should be referred to secondary care. Overall, managing menopause requires a personalized approach that takes into account a woman’s medical history, preferences, and individual symptoms.

A young woman who has never had a menstrual period before and has underdeveloped secondary sexual characteristics presents with raised FSH and LH levels. The most likely cause of her primary amenorrhoea is gonadal dysgenesis, which can be seen in syndromes such as Turner’s syndrome. In this condition, the gonads are atypically developed and may be functionless, resulting in the absence of androgen production in response to FSH and LH. This leads to underdeveloped secondary sexual characteristics and primary amenorrhoea. Asherman syndrome, imperforate hymen, Kallmann syndrome, and pregnancy are incorrect answers.

Understanding Amenorrhoea: Causes, Investigations, and Management

Amenorrhoea is a condition characterized by the absence of menstrual periods in women. It can be classified into two types: primary and secondary. Primary amenorrhoea occurs when menstruation fails to start by the age of 15 in girls with normal secondary sexual characteristics or by the age of 13 in girls with no secondary sexual characteristics. On the other hand, secondary amenorrhoea is the cessation of menstruation for 3-6 months in women with previously normal and regular menses or 6-12 months in women with previous oligomenorrhoea.

There are various causes of amenorrhoea, including gonadal dysgenesis, testicular feminization, congenital malformations of the genital tract, functional hypothalamic amenorrhoea, congenital adrenal hyperplasia, imperforate hymen, hypothalamic amenorrhoea, polycystic ovarian syndrome, hyperprolactinemia, premature ovarian failure, Sheehan’s syndrome, Asherman’s syndrome, and thyrotoxicosis. To determine the underlying cause of amenorrhoea, initial investigations such as full blood count, urea & electrolytes, coeliac screen, thyroid function tests, gonadotrophins, prolactin, and androgen levels are necessary.

The management of amenorrhoea depends on the underlying cause. For primary amenorrhoea, it is important to investigate and treat any underlying cause. Women with primary ovarian insufficiency due to gonadal dysgenesis may benefit from hormone replacement therapy to prevent osteoporosis. For secondary amenorrhoea, it is important to exclude pregnancy, lactation, and menopause in women 40 years of age or older and treat the underlying cause accordingly. It is important to note that hypothyroidism may also cause amenorrhoea.

The recommended treatment for the patient’s likely diagnosis of trichomoniasis is oral metronidazole, either as a 7-day course of 200mg or a one-time dose of 2g. Intramuscular ceftriaxone, benzathine benzylpenicillin, and oral doxycycline are not indicated for the treatment of trichomoniasis. Oral azithromycin is also not effective for this condition.

Understanding Trichomonas vaginalis and its Comparison to Bacterial Vaginosis

Trichomonas vaginalis is a type of protozoan parasite that is highly motile and flagellated. It is known to cause trichomoniasis, which is a sexually transmitted infection. The infection is characterized by symptoms such as offensive, yellow/green, frothy vaginal discharge, vulvovaginitis, and strawberry cervix. The pH level is usually above 4.5, and in men, it may cause urethritis.

To diagnose trichomoniasis, a wet mount microscopy is conducted to observe the motile trophozoites. The treatment for trichomoniasis involves oral metronidazole for 5-7 days, although a one-off dose of 2g metronidazole may also be used.

When compared to bacterial vaginosis, trichomoniasis has distinct differences. Bacterial vaginosis is caused by an overgrowth of bacteria in the vagina, while trichomoniasis is caused by a protozoan parasite. The symptoms of bacterial vaginosis include a thin, grayish-white vaginal discharge with a fishy odor, and a pH level above 4.5. Unlike trichomoniasis, bacterial vaginosis is not considered a sexually transmitted infection.

In conclusion, understanding the differences between trichomoniasis and bacterial vaginosis is crucial in diagnosing and treating these conditions effectively. Proper diagnosis and treatment can help prevent complications and improve overall health and well-being.

Breast cancer screening is offered to women aged 50-70 years through the NHS Breast Screening Programme. Mammograms are provided every three years, and women over 70 years are encouraged to make their own appointments. While the effectiveness of breast screening is debated, it is estimated that the programme saves around 1,400 lives annually.

For those with familial breast cancer, NICE guidelines recommend referral if there is a family history of breast cancer with any of the following: diagnosis before age 40, bilateral breast cancer, male breast cancer, ovarian cancer, Jewish ancestry, sarcoma in a relative under 45 years, glioma or childhood adrenal cortical carcinomas, complicated patterns of multiple cancers at a young age, or paternal history of breast cancer with two or more relatives on the father’s side. Women at increased risk due to family history may be offered screening at a younger age. Referral to a breast clinic is recommended for those with a first-degree relative diagnosed with breast cancer before age 40, a first-degree male relative with breast cancer, a first-degree relative with bilateral breast cancer before age 50, two first-degree relatives or one first-degree and one second-degree relative with breast cancer, or a first- or second-degree relative with breast and ovarian cancer.

The patient is suffering from thrush and requires antifungal medication. However, since the patient is pregnant, oral fluconazole cannot be prescribed due to its link with birth defects. Instead, metronidazole can be used to treat bacterial vaginosis and Trichomonas vaginalis.

Vaginal candidiasis, also known as thrush, is a common condition that many women can diagnose and treat themselves. Candida albicans is responsible for about 80% of cases, while other candida species cause the remaining 20%. Although most women have no predisposing factors, certain factors such as diabetes mellitus, antibiotics, steroids, pregnancy, and HIV can increase the likelihood of developing vaginal candidiasis. Symptoms include non-offensive discharge resembling cottage cheese, vulvitis, itching, vulval erythema, fissuring, and satellite lesions. A high vaginal swab is not routinely indicated if the clinical features are consistent with candidiasis. Treatment options include local or oral therapy, with oral fluconazole 150 mg as a single dose being the first-line treatment according to NICE Clinical Knowledge Summaries. If there are vulval symptoms, a topical imidazole may be added to an oral or intravaginal antifungal. Pregnant women should only use local treatments. Recurrent vaginal candidiasis is defined as four or more episodes per year by BASHH. Compliance with previous treatment should be checked, and a high vaginal swab for microscopy and culture should be performed to confirm the diagnosis. A blood glucose test may be necessary to exclude diabetes, and differential diagnoses such as lichen sclerosus should be ruled out. An induction-maintenance regime involving oral fluconazole may be considered. Induction involves taking oral fluconazole every three days for three doses, while maintenance involves taking oral fluconazole weekly for six months.

If a foetal heartbeat is detected on ultrasound in the case of an ectopic pregnancy, surgical management is necessary, and the appropriate procedure is a salpingectomy. This is the recommended course of action for a patient with no significant medical history and both fallopian tubes. Expectant management is not suitable in this scenario, as the foetal heartbeat is visible on ultrasound. Medical management with methotrexate is also not an option due to the foetal heartbeat, and mifepristone is not used for ectopic pregnancies.

Ectopic pregnancy is a serious condition that requires prompt investigation and management. Women who are stable are typically investigated and managed in an early pregnancy assessment unit, while those who are unstable should be referred to the emergency department. The investigation of choice for ectopic pregnancy is a transvaginal ultrasound, which will confirm the presence of a positive pregnancy test.

There are three ways to manage ectopic pregnancies: expectant management, medical management, and surgical management. The choice of management will depend on various criteria, such as the size of the ectopic pregnancy, whether it is ruptured or not, and the patient’s symptoms and hCG levels. Expectant management involves closely monitoring the patient over 48 hours, while medical management involves giving the patient methotrexate and requires follow-up. Surgical management can involve salpingectomy or salpingotomy, depending on the patient’s risk factors for infertility.

Salpingectomy is the first-line treatment for women with no other risk factors for infertility, while salpingotomy should be considered for women with contralateral tube damage. However, around 1 in 5 women who undergo a salpingotomy require further treatment, such as methotrexate and/or a salpingectomy. It is important to carefully consider the patient’s individual circumstances and make a decision that will provide the best possible outcome.

If a woman has Type 1 diabetes mellitus, she is at a high risk of having a baby with neural tube defects. To prevent this, she should take 5mg of folic acid daily for three months before getting pregnant until the first 12 weeks of pregnancy. Any other dosage or duration of the regime would be incorrect for her.

Folic Acid: Importance, Deficiency, and Prevention

Folic acid is a vital nutrient that is converted to tetrahydrofolate (THF) in the body. It is found in green, leafy vegetables and plays a crucial role in the transfer of 1-carbon units to essential substrates involved in the synthesis of DNA and RNA. However, certain factors such as phenytoin, methotrexate, pregnancy, and alcohol excess can cause a deficiency in folic acid. This deficiency can lead to macrocytic, megaloblastic anemia and neural tube defects.

To prevent neural tube defects during pregnancy, it is recommended that all women take 400mcg of folic acid until the 12th week of pregnancy. Women at higher risk of conceiving a child with a neural tube defect should take 5mg of folic acid from before conception until the 12th week of pregnancy. Women are considered higher risk if they or their partner has a neural tube defect, they have had a previous pregnancy affected by a neural tube defect, or they have a family history of a neural tube defect. Additionally, women with certain medical conditions such as coeliac disease, diabetes, or thalassaemia trait, or those taking antiepileptic drugs, or who are obese (BMI of 30 kg/m2 or more) are also considered higher risk.

In summary, folic acid is an essential nutrient that plays a crucial role in DNA and RNA synthesis. Deficiency in folic acid can lead to serious health consequences, including neural tube defects. However, taking folic acid supplements during pregnancy can prevent these defects and ensure a healthy pregnancy.

In the context of managing a pregnant patient with well-controlled type 1 diabetes, it is crucial to implement preventive measures that can enhance maternal and fetal health. At 12 weeks of gestation, the initiation of low-dose aspirin is recommended for women with diabetes. This intervention is aimed at reducing the risk of preeclampsia, a condition characterized by high blood pressure and potential organ dysfunction that can arise during pregnancy, particularly in women with pre-existing conditions such as diabetes. While vitamin B12 supplementation is important for certain populations, it is not routinely initiated at this stage unless there is a specific deficiency. Ascorbic acid, or vitamin C, does not have established guidelines for routine supplementation during pregnancy. Multivitamins are generally beneficial, but they are not specifically indicated to be started at 12 weeks for this patient group. Ferrous fumarate, an iron supplement, is typically reserved for cases of iron deficiency anemia, which may not be applicable in this scenario given the patient’s current health status.

Key Takeaways:

– Low-dose aspirin is recommended at 12 weeks gestation for women with diabetes to lower the risk of preeclampsia.

– Vitamin B12, ascorbic acid, multivitamins, and ferrous fumarate are not specifically indicated for initiation at this gestational age in this patient population.

– Monitoring and preventive strategies are essential in managing pregnancies complicated by pre-existing diabetes.

Hypertension during pregnancy is a common occurrence that requires careful management. In normal pregnancies, blood pressure tends to decrease in the first trimester and then gradually increase to pre-pregnancy levels by term. However, in cases of hypertension during pregnancy, the systolic blood pressure is usually above 140 mmHg or the diastolic blood pressure is above 90 mmHg. Additionally, an increase of more than 30 mmHg systolic or 15 mmHg diastolic from the initial readings may also indicate hypertension.

There are three categories of hypertension during pregnancy: pre-existing hypertension, pregnancy-induced hypertension (PIH), and pre-eclampsia. Pre-existing hypertension refers to a history of hypertension before pregnancy or elevated blood pressure before 20 weeks gestation. PIH occurs in the second half of pregnancy and resolves after birth. Pre-eclampsia is characterized by hypertension and proteinuria, and may also involve edema.

The management of hypertension during pregnancy involves the use of antihypertensive medications such as labetalol, nifedipine, and hydralazine. In cases of pre-existing hypertension, ACE inhibitors and angiotensin II receptor blockers should be stopped immediately and alternative medications should be prescribed. Women who are at high risk of developing pre-eclampsia should take aspirin from 12 weeks until the birth of the baby. It is important to carefully monitor blood pressure and proteinuria levels during pregnancy to ensure the health of both the mother and the baby.

What is the effectiveness of secondary prevention measures for women with pre-eclampsia? A-level research has shown that low-dose aspirin, when started at 12-14 weeks’ gestation, is more effective than a placebo in reducing the occurrence of pre-eclampsia in high-risk women. This treatment also reduces perinatal mortality and the risk of babies being born small for gestational age. While low molecular weight heparin may reduce placental insufficiency in pre-eclampsia, there is currently a lack of long-term safety studies. Labetalol and methyldopa are commonly used antihypertensive drugs for acute management of pre-eclampsia, but they are not given prophylactically and do not reduce intrauterine growth retardation. Unfractionated heparin has also not been proven to prevent the development of uteroplacental insufficiency.

Hypertension during pregnancy is a common occurrence that requires careful management. In normal pregnancies, blood pressure tends to decrease in the first trimester and then gradually increase to pre-pregnancy levels by term. However, in cases of hypertension during pregnancy, the systolic blood pressure is usually above 140 mmHg or the diastolic blood pressure is above 90 mmHg. Additionally, an increase of more than 30 mmHg systolic or 15 mmHg diastolic from the initial readings may also indicate hypertension.

There are three categories of hypertension during pregnancy: pre-existing hypertension, pregnancy-induced hypertension (PIH), and pre-eclampsia. Pre-existing hypertension refers to a history of hypertension before pregnancy or elevated blood pressure before 20 weeks gestation. PIH occurs in the second half of pregnancy and resolves after birth. Pre-eclampsia is characterized by hypertension and proteinuria, and may also involve edema.

The management of hypertension during pregnancy involves the use of antihypertensive medications such as labetalol, nifedipine, and hydralazine. In cases of pre-existing hypertension, ACE inhibitors and angiotensin II receptor blockers should be stopped immediately and alternative medications should be prescribed. Women who are at high risk of developing pre-eclampsia should take aspirin from 12 weeks until the birth of the baby. It is important to carefully monitor blood pressure and proteinuria levels during pregnancy to ensure the health of both the mother and the baby.

Understanding Puerperal Pyrexia

Puerperal pyrexia is a condition that occurs when a woman experiences a fever of more than 38ºC within the first 14 days after giving birth. The most common cause of this condition is endometritis, which is an infection of the lining of the uterus. Other causes include urinary tract infections, wound infections, mastitis, and venous thromboembolism.

If a woman is suspected of having endometritis, it is important to seek medical attention immediately. Treatment typically involves intravenous antibiotics such as clindamycin and gentamicin until the patient is afebrile for more than 24 hours. It is important to note that puerperal pyrexia can be a serious condition and should not be ignored. By understanding the causes and seeking prompt medical attention, women can receive the necessary treatment to recover from this condition.

After giving birth, women need to use contraception only after 21 days.

As the woman in the question is only 14 days post-partum, she does not need emergency contraception. Therefore, the advice to her would be that emergency contraception is not necessary.

After giving birth, women need to use contraception after 21 days. The progestogen-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first two days after day 21. A small amount of progestogen enters breast milk, but it is not harmful to the infant. On the other hand, the combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than six weeks post-partum. If breastfeeding is between six weeks and six months postpartum, it is a UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk post-partum. After day 21, additional contraception should be used for the first seven days. The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after four weeks.

The lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than six months post-partum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

Treatment is administered based on the individual’s exposure to the infection rather than confirmed infection.

Chlamydia is a common sexually transmitted infection caused by Chlamydia trachomatis. It is prevalent in the UK, with approximately 1 in 10 young women affected. The incubation period is around 7-21 days, but many cases are asymptomatic. Symptoms in women include cervicitis, discharge, and bleeding, while men may experience urethral discharge and dysuria. Complications can include epididymitis, pelvic inflammatory disease, and infertility.

Traditional cell culture is no longer widely used for diagnosis, with nuclear acid amplification tests (NAATs) being the preferred method. Testing can be done using urine, vulvovaginal swab, or cervical swab. Screening is recommended for sexually active individuals aged 15-24 years, and opportunistic testing is common.

Doxycycline is the first-line treatment for Chlamydia, with azithromycin as an alternative if doxycycline is contraindicated or not tolerated. Pregnant women may be treated with azithromycin, erythromycin, or amoxicillin. Patients diagnosed with Chlamydia should be offered partner notification services, with all contacts since the onset of symptoms or within the last six months being notified and offered treatment.

Adverse Effects of Hormone Replacement Therapy

Hormone replacement therapy (HRT) is a treatment that involves the use of a small dose of oestrogen, often combined with a progestogen in women with a uterus, to alleviate menopausal symptoms. While it can be effective in reducing symptoms such as hot flashes and vaginal dryness, HRT can also have adverse effects and potential complications.

Some common side-effects of HRT include nausea, breast tenderness, fluid retention, and weight gain. However, there are also more serious potential complications associated with HRT. For example, the use of HRT has been linked to an increased risk of breast cancer, particularly when a progestogen is added. The Women’s Health Initiative study found a relative risk of 1.26 at 5 years of developing breast cancer with HRT use. The risk of breast cancer is also related to the duration of use, and it begins to decline when HRT is stopped.

Another potential complication of HRT is an increased risk of endometrial cancer. Oestrogen by itself should not be given as HRT to women with a womb, as this can increase the risk of endometrial cancer. The addition of a progestogen can reduce this risk, but it is not eliminated completely. The British National Formulary states that the additional risk is eliminated if a progestogen is given continuously.

HRT has also been associated with an increased risk of venous thromboembolism (VTE), particularly when a progestogen is added. However, transdermal HRT does not appear to increase the risk of VTE. Women who are at high risk for VTE should be referred to haematology before starting any treatment, even transdermal, according to the National Institute for Health and Care Excellence (NICE).

Finally, HRT has been linked to an increased risk of stroke and ischaemic heart disease if taken more than 10 years after menopause. It is important for women considering HRT to discuss the potential risks and benefits with their healthcare provider and make an informed decision based on their individual circumstances.

Weight loss before pregnancy
Lack of proper hydration
Disruption in electrolyte balance

Hyperemesis gravidarum is an extreme form of nausea and vomiting of pregnancy that occurs in around 1% of pregnancies and is most common between 8 and 12 weeks. It is associated with raised beta hCG levels and can be caused by multiple pregnancies, trophoblastic disease, hyperthyroidism, nulliparity, and obesity. Referral criteria for nausea and vomiting in pregnancy include continued symptoms with ketonuria and/or weight loss, a confirmed or suspected comorbidity, and inability to keep down liquids or oral antiemetics. The diagnosis of hyperemesis gravidarum requires the presence of 5% pre-pregnancy weight loss, dehydration, and electrolyte imbalance. Management includes first-line use of antihistamines and oral cyclizine or promethazine, with second-line options of ondansetron and metoclopramide. Admission may be needed for IV hydration. Complications can include Wernicke’s encephalopathy, Mallory-Weiss tear, central pontine myelinolysis, acute tubular necrosis, and fetal growth issues.

If a woman with large fibroids is experiencing fertility issues, the most effective treatment option that also preserves her ability to conceive in the future is myomectomy. However, depending on the specifics of the procedure, the woman may need to consider delivery options, such as a caesarean section, due to the risk of uterine rupture.

While GnRH agonists can shrink fibroids and make them easier to remove surgically, they also temporarily turn off the ovaries, inhibiting ovulation and making pregnancy impossible during treatment. Additionally, fibroids tend to regrow after treatment is stopped. However, when combined with myomectomy, GnRH agonists can be a suitable treatment option.

Endometrial ablation, on the other hand, destroys the endometrial lining, making it impossible for an embryo to implant. Uterine artery embolisation is also not recommended for women trying to conceive, as it significantly reduces blood supply to the uterus, making it impossible for a fetus to implant and grow.

Understanding Uterine Fibroids

Uterine fibroids are non-cancerous growths that develop in the uterus. They are more common in black women and are thought to occur in around 20% of white women in their later reproductive years. Fibroids are usually asymptomatic, but they can cause menorrhagia, which can lead to iron-deficiency anaemia. Other symptoms include lower abdominal pain, bloating, and urinary symptoms. Fibroids may also cause subfertility.

Diagnosis is usually made through transvaginal ultrasound. Asymptomatic fibroids do not require treatment, but periodic monitoring is recommended. Menorrhagia secondary to fibroids can be managed with various treatments, including the levonorgestrel intrauterine system, NSAIDs, tranexamic acid, and hormonal therapies.

Medical treatment to shrink or remove fibroids may include GnRH agonists or ulipristal acetate, although the latter is not currently recommended due to concerns about liver toxicity. Surgical options include myomectomy, hysteroscopic endometrial ablation, hysterectomy, and uterine artery embolization.

Fibroids generally regress after menopause, but complications such as subfertility and iron-deficiency anaemia can occur. Red degeneration, which is haemorrhage into the tumour, is a common complication during pregnancy.